<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia - Nagler, EV - 2018 | Cochrane Library</title> <meta content="Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia - Nagler, EV - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010965.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia - Nagler, EV - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010965.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010965.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia" name="citation_title"/> <meta content="Evi V Nagler" name="citation_author"/> <meta content="Evi.Nagler@UGent.be" name="citation_author_email"/> <meta content="Maria C Haller" name="citation_author"/> <meta content="Wim Van Biesen" name="citation_author"/> <meta content="Raymond Vanholder" name="citation_author"/> <meta content="Jonathan C Craig" name="citation_author"/> <meta content="Angela C Webster" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD010965.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/06/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010965.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010965.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010965.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antidiuretic Hormone Receptor Antagonists [*therapeutic use]; Chronic Disease; Hyponatremia [blood, *drug therapy, mortality]; Length of Stay; Quality of Life; Randomized Controlled Trials as Topic; Sodium [blood]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010965.pub2&amp;doi=10.1002/14651858.CD010965.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010965\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010965\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","pt","fr","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010965.pub2",title:"Interventions for chronic non\\u2010hypovolaemic hypotonic hyponatraemia",firstPublishedDate:"Jun 28, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010965.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010965.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010965.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010965.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010965.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010965.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010965.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010965.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010965.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010965.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4830 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010965.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-sec-0087"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/appendices#CD010965-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/table_n/CD010965StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/table_n/CD010965StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#CD010965-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Evi V Nagler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#CD010965-cr-0003">Maria C Haller</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#CD010965-cr-0004">Wim Van Biesen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#CD010965-cr-0005">Raymond Vanholder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#CD010965-cr-0006">Jonathan C Craig</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information#CD010965-cr-0007">Angela C Webster</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information/en#CD010965-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 June 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010965.pub2">https://doi.org/10.1002/14651858.CD010965.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010965-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010965-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010965-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010965-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010965-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010965-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010965-abs-0001" lang="en"> <section id="CD010965-sec-0001"> <h3 class="title" id="CD010965-sec-0001">Background</h3> <p>Chronic (present &gt; 48 hours) non‐hypovolaemic hyponatraemia occurs frequently, can be caused by various conditions, and is associated with shorter survival and longer hospital stays. Many treatments, such as fluid restriction or vasopressin receptor antagonists can be used to improve the hyponatraemia, but whether that translates into improved patient‐important outcomes is less certain. </p> </section> <section id="CD010965-sec-0002"> <h3 class="title" id="CD010965-sec-0002">Objectives</h3> <p>This review aimed to 1) look at the benefits and harms of interventions for chronic non‐hypovolaemic hypotonic hyponatraemia when compared with placebo, no treatment or head‐to‐head; and 2) determine if benefits and harms vary in absolute or relative terms dependent on the specific compound within a drug class, on the dosage used, or the underlying disorder causing the hyponatraemia. </p> </section> <section id="CD010965-sec-0003"> <h3 class="title" id="CD010965-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 1 December 2017 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. We also screened the reference lists of potentially relevant studies, contacted authors, and screened the websites of regulatory agencies. </p> </section> <section id="CD010965-sec-0004"> <h3 class="title" id="CD010965-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs that compared the effects of any intervention with placebo, no treatment, standard care, or any other intervention in patients with chronic non‐hypovolaemic hypotonic hyponatraemia. We also included subgroups with hyponatraemia from studies with broader inclusion criteria (e.g. people with chronic heart failure or people with cirrhosis with or without hyponatraemia), provided we could obtain outcomes for participants with hyponatraemia from the report or the study authors. </p> </section> <section id="CD010965-sec-0005"> <h3 class="title" id="CD010965-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed risk of bias. We expressed treatment effects as mean difference (MD) for continuous outcomes (health‐related quality of life, length of hospital stay, change from baseline in serum sodium concentration, cognitive function), and risk ratio (RR) for dichotomous outcomes (death, response and rapid increase in serum sodium concentration, hypernatraemia, polyuria, hypotension, acute kidney injury, liver function abnormalities) together with 95% confidence intervals (CI). </p> </section> <section id="CD010965-sec-0006"> <h3 class="title" id="CD010965-sec-0006">Main results</h3> <p>We identified 35 studies, enrolling 3429 participants. Twenty‐eight studies (3189 participants) compared a vasopressin receptor antagonist versus placebo, usual care, no treatment, or fluid restriction. In adults with chronic, non‐hypovolaemic hypotonic hyponatraemia, vasopressin receptor antagonists have uncertain effects on death at six months (15 studies, 2330 participants: RR 1.11, 95% CI 0.92 to 1.33) due to risk of selective reporting and serious imprecision; and on health‐related quality of life because results are at serious risk of performance, selective reporting and attrition bias, and suffer from indirectness related to the validity of the Short Form Health Survey (SF‐12) in the setting of hyponatraemia. Vasopressin receptor antagonists may reduce hospital stay (low certainty evidence due to risk of performance bias and imprecision) (3 studies, 610 participants: MD ‐1.63 days, 95% CI ‐2.96 to ‐0.30), and may make little or no difference to cognitive function (low certainty evidence due to indirectness and imprecision). Vasopressin receptor antagonists probably increase the intermediate outcome of serum sodium concentration (21 studies, 2641 participants: MD 4.17 mmol/L, 95% CI 3.18 to 5.16), corresponding to two and a half as many people having a 5 to 6 mmol/L increase in sodium concentration compared with placebo at 4 to 180 days (moderate certainty evidence due to risk of attrition bias) (18 studies, 2014 participants: RR 2.49, 95% CI 1.95 to 3.18). But they probably also increase the risk of rapid serum sodium correction ‐ most commonly defined as &gt; 12 mmol/L/d (moderate certainty evidence due to indirectness) (14 studies, 2058 participants: RR 1.67, 95% CI 1.16 to 2.40) and commonly cause side‐effects such as thirst (13 studies, 1666 participants: OR 2.77, 95% CI 1.80 to 4.27) and polyuria (6 studies, 1272 participants): RR 4.69, 95% CI 1.59 to 13.85) (high certainty evidence). The potential for liver toxicity remains uncertain due to large imprecision. Effects were generally consistent across the different agents, suggesting class effect. </p> <p>Data for other interventions such as fluid restriction, urea, mannitol, loop diuretics, corticosteroids, demeclocycline, lithium and phenytoin were largely absent. </p> </section> <section id="CD010965-sec-0007"> <h3 class="title" id="CD010965-sec-0007">Authors' conclusions</h3> <p>In people with chronic hyponatraemia, vasopressin receptor antagonists modestly raise serum sodium concentration at the cost of a 3% increased risk of it being rapid. To date there is very low certainty evidence for patient‐important outcomes; the effects on mortality and health‐related quality of life are unclear and do not rule out appreciable benefit or harm; there does not appear to be an important effect on cognitive function, but hospital stay may be slightly shorter, although available data are limited. Treatment decisions must weigh the value of an increase in serum sodium concentration against its short‐term risks and unknown effects on patient‐important outcomes. Evidence for other treatments is largely absent. </p> <p>Further studies assessing standard treatments such as fluid restriction or urea against placebo and one‐another would inform practice and are warranted. Given the limited available evidence for patient‐important outcomes, any study should include these outcomes in a standardised manner. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010965-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010965-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010965-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010965-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010965-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010965-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010965-abs-0008">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010965-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010965-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010965-abs-0005" lang="en"> <h3>Interventions for chronic non‐hypovolaemic hypotonic hyponatraemia</h3> <p><b>What is the issue?</b> </p> <p>A low blood sodium concentration can be caused by many conditions and is linked to shorter survival and longer hospital stays. Many treatments, such as fluid restriction or certain water pills called vasopressin receptor antagonists can be used to increase the blood sodium concentration, as long as increases happen slowly enough to avoid brain damage. Whether these treatments also improve patient outcomes (the way patients feel, function and survive) is less clear. </p> <p><b>What did we do?</b> </p> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs that compared the effects of any intervention with placebo, no treatment, standard care, or any other intervention in patients with chronic non‐hypovolaemic hypotonic hyponatraemia. </p> <p><b>What did we find?</b> </p> <p>Our systematic search (to December 2017) identified 35 studies, enrolling 3429 patients. Vasopressin receptor antagonists have unclear effects on the risk of death and quality of life, with additional studies needed to answer these questions. They likely improve the blood sodium concentration, but it sometimes happens too quickly. In addition, people who take vasopressin receptor antagonists may experience increased thirst and urine output. There is very little information for any of the other available treatments. </p> <p><b>Conclusions</b> </p> <p>In people with low blood sodium concentration, vasopressin receptor antagonists modestly raised the sodium concentration. The effects on mortality and health‐related quality of life are unclear and do not rule out appreciable benefit or harm; there does not appear to be an important effect on cognitive function, but hospital stay may be slightly shorter, although available data are limited. Evidence for other treatments is largely absent. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010965-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010965-sec-0093"></div> <h3 class="title" id="CD010965-sec-0094">Implications for practice</h3> <section id="CD010965-sec-0094"> <p>In people with chronic hyponatraemia, vasopressin receptor antagonists modestly raise serum sodium concentration at the cost of an absolute 3% increased risk the increase being too rapid. To date there is insufficient evidence for patient‐important outcomes; the effects on mortality and health‐related quality of life are unclear and do not rule out appreciable benefit or harm; there does not appear to be an important effect on cognitive function, but hospital stay may be shorter, although available data are limited. Treatment decisions must weigh the value of an increase in serum sodium concentration against it short‐term risks and unknown effects on patient‐important outcomes. Evidence for other treatments is largely absent. </p> </section> <h3 class="title" id="CD010965-sec-0095">Implications for research</h3> <section id="CD010965-sec-0095"> <p>Further studies assessing commonly used treatments such as fluid restriction would inform practice and are warranted. Also, given the limited available evidence for patient‐important outcomes, studies with vasopressin receptor antagonists and other treatments should include these outcomes in a standardised way. Importantly, this requires validation of health‐related quality of life measures, tailored specifically to the context of hyponatraemia and international consensus on how to assess hyponatraemia‐specific symptoms. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010965-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010965-sec-0029"></div> <div class="table" id="CD010965-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vasopressin receptor antagonists versus placebo or no treatment for chronic non‐hypovolaemic hypotonic hyponatraemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vasopressin receptor antagonists versus placebo or no treatment for chronic non‐hypovolaemic hypotonic hyponatraemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> chronic non‐hypovolaemic hypotonic hyponatraemia<br/> <b>Intervention:</b> Vasopressin receptor antagonists<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vasopressin receptor antagonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death</p> <p>Follow‐up: range 2 to 180 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/> (0.92 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2330 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Interpretation: effect uncertain; may both result in 11/1000 fewer to 47/1000 more deaths within 6 months </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/> (132 to 190) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (assessed with mental component score of SF‐12<sup>4</sup>) </p> <p>Follow‐up: 30 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in health‐related quality of life in the control group ranged between 0.75 and 2.39 on a 0 to 100 point scale (worst to best) <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life in the intervention group was 4.76 higher (0.11 higher to 9.41 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>6, 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physical component score also measured in both studies; RR 1.04; CI ‐1.81 to 3.90</p> <p>Interpretation: anywhere from 0.1 to 9.5/100 points higher increase with treatment, but questionable tool for QoL measurement in hyponatraemia and unclear minimally important clinical difference </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay in the control group was 6 to 11 days <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay in the intervention group was 1.63 days lower (2.96 lower to 0.30 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function</p> <p>(assessed with various tools)</p> <p>Follow‐up: 1 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Across five studies, confidence intervals spanned the line of no effect and did not include a clinically meaningful effect </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1169 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW <sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tools used to assess cognitive function: making test B; reaction time, psychomotor, processing speeds; Mini mental state exam; overall meta‐analysis including all five studies not meaningfully possible </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline in serum sodium concentration</p> <p>Follow‐up: range 1 to 180 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in serum sodium concentration in the control group was 0.3 to 4.8 mmol/L <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in serum sodium concentration in the intervention group was 4.17 mmol/L higher (3.18 higher to 5.16 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2641 (21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serum sodium concentration (response)</p> <p>Follow‐up: range 4 to 180 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.49<br/> (1.95 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2104 (18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response most commonly defined by investigators as &gt; 5 to &gt; 6 mmol/L increase or normalisation of serum sodium concentration </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>231 per 1000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>576 per 1000<br/> (454 to 597) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rapid sodium increase</p> <p>Follow‐up: range 1 to 5 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.67<br/> (1.16 to 2.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2058 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rapid increase most commonly defined as &gt; 12 mmol/d</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/> (51 to 105) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Source of assumed baseline risk was calculated as the unweighted summed event rate in the control groups of the trials included in the meta‐analysis </p> <p><sup>2</sup> Downgraded one level because studies considered at serious risk of suffering from </p> <p>* selective reporting: 6/16 studies with treatment duration &gt; 1 week did not report death and had no protocol, accounting for 16% of the total number of participants in those studies </p> <p>* commercial sponsorship; possible financial conflict of interest of the authors: all studies sponsored by pharmaceutical companies wanting to commercialize the treatment; all save one had author lists who featured people who had received money for presentations or consultancy, or were employed by the sponsor; only used as supporting reason for downgrading. </p> <p><sup>3</sup> Downgraded two levels for imprecision. The 95% CI of the pooled estimate includes both important reduction (11/1000 fewer) and increase (47/1000 more) in death with vasopressin receptor antagonists. </p> <p><sup>4</sup> Choice of the outcome‐measure based on the fact that this was the only one reported in any of the studies. There are concerns around the validity of the SF‐12 as a measure for health‐related quality of life in the field of hyponatraemia as it gauges domains and symptoms not directly attributable to hyponatraemia. </p> <p><sup>5</sup> Source of the assumed baseline risk was the range of outcomes in the control groups of the trials included in the meta‐analysis </p> <p><sup>6</sup> Downgraded one level because studies considered seriously at risk of suffering from </p> <p>* Performance bias: self‐reported outcome, participants likely unblinded to treatment due to polyuria as side effect </p> <p>* Selective reporting bias: both mental and physical component score of SF‐12 measured; at week 1 or 2 and day 30 using two different analytic techniques. Only data at day 30 available for analysis. </p> <p>* Attrition bias: overall 37% of data missing, unknown whether missing at random or not. </p> <p>* Commercial sponsorship or possible financial conflict of interest of authors: both studies were sponsored by the company seeking to commercialise the treatment; both had author lists who featured people who had received money for presentations or consultancy, or were employed by the sponsor; only using as supporting argument for downgrading </p> <p><sup>7</sup> Downgraded one level for indirectness due to concerns around validity of the SF‐12 for measuring quality of life in the context of hyponatraemia and one level for imprecision: only studied in two studies. </p> <p><sup>8</sup> Downgraded one level because studies considered seriously at risk of suffering from performance bias: participants and personnel likely unblinded to treatment due to polyuria as side effect; this could have influenced self‐reported and professional appreciation of clinical condition and so have influenced decision to discharge from hospital. </p> <p><sup>9</sup> Downgraded one level for imprecision. The 95% CI of the pooled estimate includes both negligible shortening (0.3 days shorter) and clinically important shortening (3 days shorter) of hospital stay with vasopressin receptor antagonists. </p> <p><sup>10</sup> Downgraded two levels for indirectness and imprecision. Only studied in 5/28 studies, with most data for lixivaptan, and other studies not reaching the optimal information size. </p> <p><sup>11</sup> Downgraded one level because we considered studies seriously at risk of suffering from </p> <p>* Attrition bias: 7/21 studies, accounting for 53% of the total number of participants in those studies at high risk of bias either due to true attrition or because a repeated measures analytic technique was used with all measurements of serum sodium concentration included until patient attrition, which we judged would likely have overestimated the treatment effect. </p> <p>*Commercial sponsorship; only used as supporting argument.</p> <p><sup>12</sup> Downgraded one level for indirectness; risks controlled in tightly organised randomised trial with several measurements of serum sodium concentration daily to avoid rapid correction. In real life, risk of rapid correction likely greater. Commercial sponsorship bias; only used as supporting argument. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010965-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010965-sec-0030"></div> <section id="CD010965-sec-0031"> <h3 class="title" id="CD010965-sec-0031">Description of the condition</h3> <p>Hypotonic hyponatraemia is a common condition, occurring in up to 60% of people admitted to hospitals, depending on the definition of hyponatraemia, the types of patients who are studied and the healthcare facility to which these patients are admitted (<a href="./references#CD010965-bbs2-0093" title="UpadhyayA , JaberBL , MadiasNE . Epidemiology of hyponatremia. Seminars in Nephrology2009;29(3):227‐38. [MEDLINE: 19523571] ">Upadhyay 2009</a>). Hypotonic hyponatraemia is usually defined as a serum sodium concentration &lt; 135 mmol/L with an osmolality &lt; 285 mOsm/kg (<a href="./references#CD010965-bbs2-0088" title="ReynoldsRM , PadfieldPL , SecklJR . Disorders of sodium balance. BMJ2006;332(7543):702‐5. [MEDLINE: 16565125] ">Reynolds 2006</a>). It develops when the body retains an excess of water relative to the amount of sodium. It can be caused by intrinsic kidney disease but usually results from incomplete suppression of vasopressin activity despite decreased tonicity of the plasma. In situations of decreased circulating blood volume, vasopressin release is increased in a physiologic response to maintain haemodynamic homeostasis. This occurs either with true volume depletion or with reduced effective arterial circulating volume, as seen in heart failure, liver cirrhosis or nephrotic syndrome. In the syndrome of inappropriate antidiuretic hormone secretion, the increased release of vasopressin is non‐haemodynamic and can have multiple causes including ectopic production of vasopressin by a variety of tumours (<a href="./references#CD010965-bbs2-0095" title="VerbalisJG , GoldsmithSR , GreenbergA , KorzeliusC , SchrierRW , SternsRH , et al. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. American Journal of Medicine2013;126(10 Suppl 1):S1‐42. [MEDLINE: 17981159] ">Verbalis 2013</a>). </p> <p>When plasma tonicity is low, water tends to enter the cells and causes them to swell. If blood sodium concentrations drop rapidly (within a 48 hour period), the swelling of brain cells may lead to brain oedema, brain stem herniation and eventually even death. Fortunately, when blood sodium concentrations drop more gradually, brain cells adapt to their hypo‐osmolar surroundings and prevent swelling by the transport of solutes from the intracellular to the extracellular compartments. As a consequence, immediate symptoms attributable to chronic hyponatraemia are usually less severe than for acute hyponatraemia (<a href="./references#CD010965-bbs2-0088" title="ReynoldsRM , PadfieldPL , SecklJR . Disorders of sodium balance. BMJ2006;332(7543):702‐5. [MEDLINE: 16565125] ">Reynolds 2006</a>). Nevertheless, people with chronic hyponatraemia have reduced attention and less stable gait than those without hyponatraemia (<a href="./references#CD010965-bbs2-0087" title="RenneboogB , MuschW , VandemergelX , MantoMU , DecauxG . Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. American Journal of Medicine2006;119(71):e1‐8. [MEDLINE: 16431193] ">Renneboog 2006</a>). They fall more often and have increased risk of osteoporosis and bone fractures (<a href="./references#CD010965-bbs2-0073" title="ArampatzisS , GaetckeLM , FunkGC , SchwartzC , MohauptM , ZimmermannH , et al. Diuretic‐induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department. Maturitas2013;75(1):81‐6. [MEDLINE: 23489552] ">Arampatzis 2013</a>; <a href="./references#CD010965-bbs2-0081" title="HoornEJ , RivadeneiraF , vanMeursJB , ZiereG , StrickerBH , HofmanA , et al. Mild hyponatremia as a risk factor for fractures: the Rotterdam study. Journal of Bone &amp; Mineral Research2011;26(8):1822‐8. [MEDLINE: 21381111] ">Hoorn 2011</a>; <a href="./references#CD010965-bbs2-0083" title="KinsellaS , MoranS , SullivanMO , MolloyMG , EustaceJA . Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clinical Journal of The American Society of Nephrology: CJASN2010;5(2):275‐80. [MEDLINE: 20056759] ">Kinsella 2010</a>; <a href="./references#CD010965-bbs2-0087" title="RenneboogB , MuschW , VandemergelX , MantoMU , DecauxG . Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. American Journal of Medicine2006;119(71):e1‐8. [MEDLINE: 16431193] ">Renneboog 2006</a>; <a href="./references#CD010965-bbs2-0094" title="VerbalisJG , BarsonyJ , SugimuraY , TianY , AdamsDJ , CarterEA , et al. Hyponatremia‐induced osteoporosis. Journal of Bone &amp; Mineral Research2010;25(3):554‐63. [MEDLINE: 19751154] ">Verbalis 2010</a>). Finally, they stay in hospital longer and have an increased risk of death, even when sodium concentrations are only mildly decreased and underlying or comorbid conditions are adjusted for (<a href="./references#CD010965-bbs2-0096" title="WaldR , JaberBL , PriceLL , UpadhyayA , MadiasNE . Impact of hospital‐associated hyponatremia on selected outcomes. Archives of Internal Medicine2010;170(3):294‐302. [MEDLINE: 20142578] ">Wald 2010</a>). </p> </section> <section id="CD010965-sec-0032"> <h3 class="title" id="CD010965-sec-0032">Description of the intervention</h3> <p>It is accepted that acute hypotonic hyponatraemia requires an immediate increase in serum sodium concentration to prevent severe neurologic complications (<a href="./references#CD010965-bbs2-0075" title="EllisonDH , BerlT . Clinical practice. The syndrome of inappropriate antidiuresis. New England Journal of Medicine2007;356(20):2064‐72. [MEDLINE: 17507705] ">Ellison 2007</a>). What to do with chronic hypotonic hyponatraemia is less clear. Firstly, chronic non‐hypovolaemic hypotonic hyponatraemia has been treated under the assumption that increasing the sodium concentration improves important health outcomes; that patients live longer, feel better and are hospitalised less frequently. Although several observational studies have indicated an association between hyponatraemia and undesirable outcomes, it is still unclear whether correcting the hyponatraemia improves them (<a href="./references#CD010965-bbs2-0093" title="UpadhyayA , JaberBL , MadiasNE . Epidemiology of hyponatremia. Seminars in Nephrology2009;29(3):227‐38. [MEDLINE: 19523571] ">Upadhyay 2009</a>; <a href="./references#CD010965-bbs2-0096" title="WaldR , JaberBL , PriceLL , UpadhyayA , MadiasNE . Impact of hospital‐associated hyponatremia on selected outcomes. Archives of Internal Medicine2010;170(3):294‐302. [MEDLINE: 20142578] ">Wald 2010</a>). Secondly, once brain cells have adapted to their hypo‐osmolar environment, they become vulnerable to osmotic demyelination in case the hypo‐osmolar environment is restored. Although rare, osmotic demyelination is a devastating neurologic complication that may occur when the myelin sheath around pontine and extrapontine neurons breaks down after rapid rises in serum sodium concentration. It very rarely does if the increases stay below 8 to 12 mmol/L/24 h and 18 mmol/L/48 h ‐ accepted limits depending on risk factors such as older age, malnutrition and alcohol abuse (<a href="./references#CD010965-bbs2-0072" title="AdrogueHJ , MadiasNE . The challenge of hyponatremia. Journal of the American Society of Nephrology2012;23(7):1140‐8. [MEDLINE: 22626822] ">Adrogue 2012</a>; <a href="./references#CD010965-bbs2-0075" title="EllisonDH , BerlT . Clinical practice. The syndrome of inappropriate antidiuresis. New England Journal of Medicine2007;356(20):2064‐72. [MEDLINE: 17507705] ">Ellison 2007</a>; <a href="./references#CD010965-bbs2-0088" title="ReynoldsRM , PadfieldPL , SecklJR . Disorders of sodium balance. BMJ2006;332(7543):702‐5. [MEDLINE: 16565125] ">Reynolds 2006</a>). Treatment for chronic hypotonic hyponatraemia must balance the uncertain benefit of increasing the sodium concentration against the risk of complications due to overly rapid correction. </p> </section> <section id="CD010965-sec-0033"> <h3 class="title" id="CD010965-sec-0033">How the intervention might work</h3> <p>Whatever the underlying cause, chronic non‐hypovolaemic hypotonic hyponatraemia usually results from urine being insufficiently dilute to maintain serum osmolality within the normal range (<a href="./references#CD010965-bbs2-0071" title="AdrogueHJ , MadiasNE . Hyponatremia. New England Journal of Medicine2000;342(21):1581‐9. [MEDLINE: 10824078] ">Adrogue 2000</a>). Several treatment strategies can be used to try overcoming this (<a href="./references#CD010965-bbs2-0072" title="AdrogueHJ , MadiasNE . The challenge of hyponatremia. Journal of the American Society of Nephrology2012;23(7):1140‐8. [MEDLINE: 22626822] ">Adrogue 2012</a>; <a href="./references#CD010965-bbs2-0075" title="EllisonDH , BerlT . Clinical practice. The syndrome of inappropriate antidiuresis. New England Journal of Medicine2007;356(20):2064‐72. [MEDLINE: 17507705] ">Ellison 2007</a>; <a href="./references#CD010965-bbs2-0095" title="VerbalisJG , GoldsmithSR , GreenbergA , KorzeliusC , SchrierRW , SternsRH , et al. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. American Journal of Medicine2013;126(10 Suppl 1):S1‐42. [MEDLINE: 17981159] ">Verbalis 2013</a>). </p> <p> <ol id="CD010965-list-0001"> <li> <p>Restriction of fluid intake aims to decrease the amount of free water needing excretion.</p> </li> <li> <p>Urea and mannitol improve electrolyte‐free water clearance by increasing urine osmolality and creating osmotic diuresis (<a href="./references#CD010965-bbs2-0084" title="LindnerG , SchwarzC , FunkGC . Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients. Nephrology Dialysis Transplantation2012;27(3):962‐7. [MEDLINE: 21810766] ">Lindner 2012</a>). </p> </li> <li> <p>Loop diuretics, such as furosemide, bumetanide and ethacrynic acid, impair free‐water absorption in the collecting duct by reducing the hypertonicity of the renal medulla. </p> </li> <li> <p>Corticosteroids with a mineralocorticoid effect increase renal sodium retention by active reabsorption of sodium in the principal cells of the cortical collecting tubule. </p> </li> <li> <p>Demeclocycline, lithium, phenytoin and vasopressin receptor antagonists act by pharmacologically inhibiting the effect of antidiuretic hormone on the principal cells of the collecting duct, thereby limiting insertion of water channels in the luminal membrane and thus preventing free water reabsorption.  </p> </li> </ol> </p> <p>As hyponatraemia with true volume depletion (chronic hypovolaemic hypotonic hyponatraemia) is treated by restoring volume with water and salt, we do not cover it in this review. </p> </section> <section id="CD010965-sec-0034"> <h3 class="title" id="CD010965-sec-0034">Why it is important to do this review</h3> <p>The benefits and harms of treatments for chronic non‐hypovolaemic hypotonic hyponatraemia have not been formally evaluated in a systematic review. Two systematic reviews have explored the efficacy and safety of vasopressin receptor antagonists (e.g. conivaptan, lixivaptan, satavaptan, tolvaptan) versus placebo, no treatment or fluid restriction (<a href="./references#CD010965-bbs2-0082" title="JaberBL , AlmarzouqiL , BorgiL , SeabraVF , BalkEM , MadiasNE . Short‐term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. American Journal of Medicine2011;124(10):977.e1‐9. [MEDLINE: 21962320] ">Jaber 2011</a>; <a href="./references#CD010965-bbs2-0089" title="Rozen‐ZviB , YahavD , GheorghiadeM , KorzetsA , LeiboviciL , GafterU . Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta‐analysis. American Journal of Kidney Diseases2010;56(2):325‐37. [MEDLINE: 20538391] ">Rozen‐Zvi 2010</a>), but to our knowledge there has been no attempt to compare them with any other intervention or to compare any of the other interventions versus placebo or against one another. </p> <p>Both systematic reviews have found an early increase in serum sodium concentration, but no improvement in outcomes important to patients. Indeed, most randomised controlled trials (RCTs) have evaluated short‐term and surrogate outcomes only, making it difficult to adequately asses any expected benefit in the long‐term. Since the most recent systematic review was published, 12 additional RCTs comparing vasopressin receptor antagonists versus control have been completed, increasing the total sample size by at least 50%. Although outcomes are still mostly surrogate and short‐term, the largest study was terminated early due to a numeric imbalance in the number of early deaths in the experimental group (<a href="./references#CD010965-bbs2-0076" title="USFood , DrugAdministration . FDA briefing document for the Cardiovascular and Renal Drug Advisory (CRDAC) ‐ Drug: Lixivaptan. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm318867.pdf (accessed 30 January 2014). ">FDA 2012</a>). Two vasopressin receptor antagonists have received wide‐spread regulatory approval, but indications and permitted treatment durations vary among regions. Divergent interpretations of survival and harms data are a likely cause. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010965-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010965-sec-0035"></div> <p>This review aimed to:</p> <p> <ol id="CD010965-list-0002"> <li> <p>Look at the benefits and harms of interventions for chronic non‐hypovolaemic hypotonic hyponatraemia when compared with placebo, no treatment or head‐to‐head; </p> </li> <li> <p>Determine if benefits and harms vary in absolute or relative terms dependent on the specific compound within a drug class, on the dosage used, or the underlying disorder causing the hyponatraemia. </p> </li> </ol> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010965-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010965-sec-0036"></div> <section id="CD010965-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010965-sec-0038"> <h4 class="title">Types of studies</h4> <p>All RCTs and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at interventions for chronic, non‐hypovolaemic hypotonic hyponatraemia. </p> <p>We also included data for hyponatraemia subgroups within studies with broader inclusion criteria (e.g. people with chronic heart failure or people with cirrhosis with or without hyponatraemia) which report outcomes for participants with hyponatraemia, or where we could obtain these subgroup data from the study authors. </p> </section> <section id="CD010965-sec-0039"> <h4 class="title">Types of participants</h4> <section id="CD010965-sec-0040"> <h5 class="title">Inclusion criteria</h5> <p> <ul id="CD010965-list-0003"> <li> <p>Adults and children beyond the neonatal period (the interval from birth to 28 days of age) </p> </li> <li> <p>Chronic, hypotonic hyponatraemia: presence of hyponatraemia &gt; 48 hours, serum osmolality &lt; 285 mOsm/kg and serum sodium concentration &lt; 135 mmol/L, or as defined by authors); not requiring immediate treatment and due to: </p> <ul id="CD010965-list-0004"> <li> <p>decreased effective circulating volume in the setting of heart failure, liver cirrhosis or nephrotic syndrome; </p> </li> <li> <p>inappropriate antidiuresis, associated with any underlying condition (includes syndrome of inappropriate antidiuretic hormone secretion and nephrogenic syndrome of inappropriate antidiuresis); or </p> </li> <li> <p>impaired renal dilutional capacity due to kidney disease.</p> </li> </ul> </li> </ul> </p> <p>Sodium concentrations can be measured in any type of blood sample (e.g. serum, plasma, whole blood, venous, arterial, capillary) using any measurement method (e.g. flame emission spectrophotometry, direct or indirect reading potentiometry by an ion‐selective electrode) in any setting (e.g. central laboratory, local laboratory, point of care device). </p> </section> <section id="CD010965-sec-0041"> <h5 class="title">Exclusion criteria</h5> <p> <ul id="CD010965-list-0005"> <li> <p>Children in the neonatal period (the interval from birth to 28 days of age)</p> </li> <li> <p>Isotonic or hypertonic hyponatraemia (osmolality ≥ 285 mOsm/kg)</p> </li> <li> <p>Hyponatraemia due to true (extracellular) volume depletion, such as from third spacing (type of fluid leakage into interstitial spaces seen in pancreatitis, bowel obstruction, sepsis), and gastrointestinal, or renal sodium loss </p> </li> <li> <p>Hyponatraemia due to secondary adrenal insufficiency or hypothyroidism</p> </li> <li> <p>Hyponatraemia due to primary psychogenic polydipsia</p> </li> <li> <p>Patients treated with any form of dialysis or extracorporeal ultrafiltration.</p> </li> </ul> </p> </section> </section> <section id="CD010965-sec-0042"> <h4 class="title">Types of interventions</h4> <p>We included studies of any degree of fluid restriction or any drug treatment that has the aim of increasing the sodium concentration. Any dose or route of administration is permitted, and interventions can be compared with placebo, no treatment, a different dose of the same or different interventions, different administration routes of the same or different interventions, or different combinations of interventions. </p> <p>Treatments included (but were not limited to):</p> <p> <ul id="CD010965-list-0006"> <li> <p>vasopressin receptor antagonists (conivaptan, mozavaptan, lixivaptan, satavaptan, tolvaptan) </p> </li> <li> <p>fluid restriction</p> </li> <li> <p>urea</p> </li> <li> <p>mannitol</p> </li> <li> <p>loop diuretics (furosemide, bumetanide, ethacrynic acid)</p> </li> <li> <p>corticosteroids (hydrocortisone or equivalent, fludrocortisone)</p> </li> <li> <p>demeclocycline</p> </li> <li> <p>lithium</p> </li> <li> <p>phenytoin.</p> </li> </ul> </p> <p>We excluded studies in which any form of dialysis treatment was given to correct serum sodium concentration. </p> </section> <section id="CD010965-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p>We assessed outcomes up to one week, up to one, two and six months, and up to one and five years. </p> <section id="CD010965-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010965-list-0007"> <li> <p>Death (all‐cause mortality)</p> </li> <li> <p>Health‐related quality of life and specifically symptoms attributed to hyponatraemia by trialists. </p> </li> </ul> </p> </section> <section id="CD010965-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010965-list-0008"> <li> <p>Length of hospital stay</p> </li> <li> <p>Serum sodium concentration (mmol/L) at end of treatment or change from beginning to end of treatment </p> </li> <li> <p>Response defined as increase of ≥ 5 mmol/L or normalisation of serum sodium concentration (≥ 135 to 145 mmol/L, or as defined by the authors) </p> </li> <li> <p>Outcomes related to over‐correction of serum sodium concentration</p> <ul id="CD010965-list-0009"> <li> <p>Incidence of hypernatraemia (serum sodium concentration &gt; 145 mmol/L, or as defined by the authors) </p> </li> <li> <p>Rapid increase in serum sodium concentration (increase in serum sodium concentration &gt; 8 to 12 mmol/L in 24 h or &gt; 18 mmol/L in 48h, or as defined by the authors) </p> </li> <li> <p>Incidence of osmotic demyelination syndrome, previously known as central pontine and extrapontine myelinolysis (diagnosed clinically, by MRI, or post mortem) </p> </li> </ul> </li> <li> <p>Any treatment‐specific side effects as defined by authors</p> <ul id="CD010965-list-0010"> <li> <p>AKI (demeclocycline, mannitol, loop diuretics)</p> </li> <li> <p>Chronic kidney disease (lithium)</p> </li> <li> <p>Hypotension (mannitol, loop diuretics, vasopressin receptor antagonists)</p> </li> <li> <p>Thirst (mannitol, loop diuretics, fluid restriction, vasopressin receptor antagonists)</p> </li> <li> <p>Central nervous system symptoms (phenytoin)</p> </li> <li> <p>Polyuria (mannitol, loop diuretics, vasopressin receptor antagonists)</p> </li> <li> <p>Any other adverse event as reported by trialists</p> </li> </ul> </li> <li> <p>Treatment discontinuation or switch</p> </li> </ul> </p> </section> </section> </section> <section id="CD010965-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010965-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 1 December 2017 through contact with the Information Specialist using search terms relevant to this review. The Specialised Register contains studies identified from the following sources: </p> <p> <ol id="CD010965-list-0011"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals and the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD010965-sec-0099">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD010965-sec-0048"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD010965-list-0012"> <li> <p>Reference lists of clinical practice guidelines, review articles and relevant studies.</p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies. </p> </li> <li> <p>Point‐of‐care sources such as Dynamed and UpToDate as well as US Food and Drug Administration (FDA) and European Medicines Agency (EMA) applications. </p> </li> </ol> </p> </section> </section> <section id="CD010965-sec-0049"> <h3 class="title" id="CD010965-sec-0049">Data collection and analysis</h3> <section id="CD010965-sec-0050"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies possibly relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however studies and reviews that possibly included relevant data or information on studies of interest for our analysis were retained initially. Two authors independently assessed retrieved abstracts and, if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD010965-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions these data were used. </p> </section> <section id="CD010965-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD010965-bbs2-0080" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD010965-sec-0100">Appendix 2</a>). </p> <p> <ul id="CD010965-list-0013"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD010965-list-0014"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD010965-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. death, number of patients with serum sodium concentration increase of ≥ 5 mmol/L, number of patients that develop hypernatraemia, number of patients with rapid increase in serum sodium concentration, number of patients that develop osmotic demyelination syndrome), individual study results were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (e.g. length of hospital stay, serum sodium concentration at the end of the study or its change from beginning to the end of treatment), results were expressed as the mean difference (MD). For outcomes reported both as dichotomous and continuous data (thirst), we presented individual study results as odds ratios (OR), by converting standardized mean differences to the natural logarithm of the odds ratios (<a href="./references#CD010965-bbs2-0080" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010965-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>If studies had multiple treatment groups, we tried to collapse these into one where appropriate to enable single pair wise comparison (e.g. collapsing three groups of different doses of vasopressin receptor antagonists into one group and including them in single pair wise comparison versus placebo) (<a href="./references#CD010965-bbs2-0080" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010965-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original authors was requested by emailing the corresponding author. If no response or insufficient information was retrieved, we subsequently emailed the sponsor. Any relevant information obtained in this manner was included in the review. Evaluation of important numerical data such as screened, randomised patients as well as intention‐to‐treat, as‐treated and per‐protocol population was performed. Attrition rates, for example drop‐outs, losses to follow‐up and withdrawals were investigated. Issues of missing data and imputation methods (for example, last‐observation‐carried‐forward) were critically appraised (<a href="./references#CD010965-bbs2-0080" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010965-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi<sup>2</sup> test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with I<sup>2</sup> calculated to measure the proportion of total variation in the estimates of treatment effect that was due to heterogeneity beyond chance (<a href="./references#CD010965-bbs2-0079" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I<sup>2</sup> values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD010965-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots were used to assess for the potential existence of small study bias. If we suspected asymmetry on visual inspection and the analysis included &gt; 10 studies, we conducted formal hypothesis testing, using Egger's test for continuous outcomes and Peter's regression test for dichotomous outcomes (<a href="./references#CD010965-bbs2-0080" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010965-sec-0058"> <h4 class="title">Data synthesis</h4> <p>Where feasible and appropriate, data were pooled using the random‐effects model. Dichotomous outcome results were expressed as risk ratio (RR) and continuous outcome results were expressed as mean difference (MD), both with 95% confidence intervals. For outcomes reported both as dichotomous and continuous data (thirst), we converted standardized mean differences to log‐transformed odds ratios, combined them using the generic inverse‐variance method and expressed the overall effect estimate as an odds ratio with its 95% confidence interval (<a href="./references#CD010965-bbs2-0080" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Although the underlying conditions causing hyponatraemia are very different, the mechanism by which hyponatraemia develops is similar in that vasopressin activity plays a role in most forms of the disorder. We believe it justified pooled analysis across subgroups of participants with different underlying conditions. </p> <p>We summarised the quality of the evidence together with absolute treatment effects based on estimated baseline risks by using the Grading of Recommendations Assessment, Development, and Evaluation guidelines (<a href="./references#CD010965-bbs2-0077" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). To estimate the absolute number of people with hyponatraemia who avoided death or incurred a rapid increase in serum sodium concentration with vasopressin receptor antagonists, the risk estimate and 95% CI were obtained from the control arm of the corresponding meta‐analyses. </p> </section> <section id="CD010965-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We analysed data for death, length of hospital stay, change from baseline and response in serum sodium concentration, cognitive function and outcomes related to over correction of serum sodium concentration within subgroups of participants dependent on the type of vasopressin receptor antagonist they were treated with. Additional prespecified subgroup analyses and univariate random effects meta‐regression were conducted to explore potential sources of heterogeneity in effects of vasopressin receptor antagonists on death, change in serum sodium concentration and rapid increase in serum sodium concentration. The potential sources of heterogeneity included type of vasopressin receptor antagonist under evaluation, the underlying condition causing the hyponatraemia (with as non‐prespecified categories studies only including participants with inappropriate antidiuresis; studies only including participants with heart failure or liver cirrhosis or studies including both), mean baseline serum sodium concentration, treatment duration and risk of selection bias. Meta‐regression was undertaken on the log RR scale for categorical outcomes using Comprehensive Meta‐Analysis<sup>®</sup> software, each study weighting equal to the inverse of the variance of the estimate for that study, with between study variance estimated using the restricted the method of moments. Results were expressed as the ratio of the RR within each subgroup for categorical explanatory variables and per one unit increase for continuous variables. </p> </section> <section id="CD010965-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>In addition to estimating treatment effects using random effects models, we also estimated fixed effects models to ensure robustness of the model chosen and susceptibility to outliers. Finally we also assessed whether including the number of deaths during follow‐up (in contrast to only including those occurring during treatment) affected the estimate of the effect of treatment on all‐cause mortality. </p> <section id="CD010965-sec-0061"> <h5 class="title">'Summary of findings' tables</h5> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD010965-bbs2-0090" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD010965-bbs2-0077" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD010965-bbs2-0091" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD010965-list-0015"> <li> <p>Death</p> </li> <li> <p>Health‐related quality of life, assessed with the mental component score and physical component score of the Short Form Health Survey (SF‐12) </p> </li> <li> <p>Cognitive function</p> </li> <li> <p>Length of hospital stay</p> </li> <li> <p>Change from baseline in serum sodium concentration</p> </li> <li> <p>Response of serum sodium concentration: defined as 4 to 6 mmol/L increase or normalisation</p> </li> <li> <p>Rapid sodium increase</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010965-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010965-sec-0062"></div> <section id="CD010965-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD010965-sec-0064"> <h4 class="title">Results of the search</h4> <p>We identified 1954 citations through electronic searches conducted in 1 December 2017. We found 16 additional reports by screening the reference lists, contacting authors, conducting online searches for full reports of included abstracts, searching online trial registries, and screening the website of regulatory agencies. We reviewed in detail 157 reports, which led to the inclusion of 111 reports of 35 unique studies including 3429 participants (<a href="#CD010965-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010965-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010965-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010965-sec-0065"> <h4 class="title">Included studies</h4> <p>Twenty‐eight studies (providing data for 3189 participants) compared a vasopressin receptor antagonist versus placebo, usual care or no treatment (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>; <a href="./references#CD010965-bbs2-0034" title="YangP . Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]. Heart2013;99(Suppl 3):A221. [EMBASE: 71317230] ">Yang 2013</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>), or versus fluid restriction (<a href="./references#CD010965-bbs2-0011" title="GheorghiadeM , GottliebSS , UdelsonJE , KonstamMA , CzerwiecF , OuyangJ , et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. American Journal of Cardiology2006;97(7):1064‐7. [MEDLINE: 16563917] ">Gheorghiade 2006</a>). Studied vasopressin receptor antagonists included conivaptan (<a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>), lixivaptan (<a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>), satavaptan (<a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>), tolvaptan (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0011" title="GheorghiadeM , GottliebSS , UdelsonJE , KonstamMA , CzerwiecF , OuyangJ , et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. American Journal of Cardiology2006;97(7):1064‐7. [MEDLINE: 16563917] ">Gheorghiade 2006</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0034" title="YangP . Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]. Heart2013;99(Suppl 3):A221. [EMBASE: 71317230] ">Yang 2013</a>) and M0002 ‐ also termed SPD556 or RWJ 351647 (<a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>). Two studies assessed different doses conivaptan (<a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>) or tolvaptan (<a href="./references#CD010965-bbs2-0030" title="ShoafSE , BricmontP , DandurandA . Low‐dose tolvaptan PK/PD: Comparison of subjects with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) to healthy adults [abstract]. Clinical Pharmacology and Therapeutics2017;101(Suppl 1):S88. [EMBASE: 614166327] ShoafSE , BricmontP , DandurandA . Low‐dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults. European Journal of Clinical Pharmacology2017;73(11):1399‐408. [MEDLINE: 28803333] ">Shoaf 2017</a>) </p> <p><a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a> (50 participants) compared fluid restriction with normal maintenance fluid in children with bacterial meningitis and reported data for the subgroup with hyponatraemia (26 participants). <a href="./references#CD010965-bbs2-0006" title="DzauVJ , HollenbergNK . Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine1984;100(6):777‐82. [MEDLINE: 6372563] ">Dzau 1984</a> (14 participants) compared captopril + furosemide versus furosemide alone in adults with decompensated heart failure. <a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a> (24 participants) compared infusion of human salt poor albumin in combination with fluid and sodium restriction versus fluid and sodium restriction alone in patients with liver cirrhosis and ascites. <a href="./references#CD010965-bbs2-0014" title="HayesPC , WilliamsR . Oral urea in the treatment of hyponatraemic ascites [abstract]. Gut1987;28(10):A1386. [CENTRAL: CN‐00221198] ">Hayes 1987</a> (10 participants) compared early versus delayed administration of urea, and <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a> (19 participants) compared a change in prescribed medications versus standard care in elderly patients admitted to the internal medicine ward or residents of the nursing home of the same institution. </p> <p>Twenty‐eight studies were conducted specifically in participants with hyponatraemia (<a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0006" title="DzauVJ , HollenbergNK . Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine1984;100(6):777‐82. [MEDLINE: 6372563] ">Dzau 1984</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0011" title="GheorghiadeM , GottliebSS , UdelsonJE , KonstamMA , CzerwiecF , OuyangJ , et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. American Journal of Cardiology2006;97(7):1064‐7. [MEDLINE: 16563917] ">Gheorghiade 2006</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0014" title="HayesPC , WilliamsR . Oral urea in the treatment of hyponatraemic ascites [abstract]. Gut1987;28(10):A1386. [CENTRAL: CN‐00221198] ">Hayes 1987</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a>; <a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>; <a href="./references#CD010965-bbs2-0034" title="YangP . Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]. Heart2013;99(Suppl 3):A221. [EMBASE: 71317230] ">Yang 2013</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>). For five studies, participants with hyponatraemia formed a subgroup of a larger study including both participants with and without hyponatraemia (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a><a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a>). </p> <p>Studies included on average mostly older adults (median 65 years, interquartile range 5) with moderate hyponatraemia (median 129 mmol/L; range 124 to 133). Participants had as primary cause of hyponatraemia a syndrome of inappropriate antidiuresis in nine studies (<a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>), heart failure in seven studies (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0006" title="DzauVJ , HollenbergNK . Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine1984;100(6):777‐82. [MEDLINE: 6372563] ">Dzau 1984</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0034" title="YangP . Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]. Heart2013;99(Suppl 3):A221. [EMBASE: 71317230] ">Yang 2013</a>) and liver cirrhosis in six studies (<a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0014" title="HayesPC , WilliamsR . Oral urea in the treatment of hyponatraemic ascites [abstract]. Gut1987;28(10):A1386. [CENTRAL: CN‐00221198] ">Hayes 1987</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>). The others included a mixed group of patients. Sample sizes varied and were generally small (median 69 participants; range 6 to 652). Treatment was mostly short‐term (median 8 days; range 1 to 365). Data for at least one outcome of interest were available from 31 studies and 3365 participants, two studies reported no numeric data (<a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>). </p> </section> <section id="CD010965-sec-0066"> <h4 class="title">Excluded studies</h4> <p>We excluded 35 studies (46 reports). Thirty‐three did not include the appropriate population, with participants either not having hyponatraemia at randomisation (<a href="./references#CD010965-bbs2-0037" title="AlbertNM , NutterB , ForneyJ , SlifcakE , TangWH . A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT‐HF). Journal of Cardiac Failure2013;19(1):1‐9. [MEDLINE: 23273588] ">Albert 2013</a>; <a href="./references#CD010965-bbs2-0041" title="DeVitaS , QuartuccioL , IsolaM , MasoliniP , SaccoS , DeMarchiG , et al. A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome [abstract]. Arthritis &amp; Rheumatism2010; Vol. 62:2201. [EMBASE: 70380187] DeVitaS , QuartuccioL , IsolaM , MazzaroC , ScainiP , LenziM , et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis &amp; Rheumatism2012; Vol. 64, issue 3:843‐53. [MEDLINE: 22147661] DeVitaS , QuartuccioL , MasoliniP , StefaniaS , DeMarchiG , ZabottiA , et al. A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment (BAT) in patients with mixed cryoglobulinemia syndrome [abstract no: OP0120]. Annals of Rheumatic Diseases2010; Vol. 69:93. QuartuccioL , ZulianiF , CorazzaL , ScainiP , ZaniR , LenziM , et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV‐related cryoglobulinemic vasculitis: Long‐term follow up data of a randomized controlled multicentre study. Journal of Autoimmunity2015;63:88‐93. [MEDLINE: 26255249] QuartuccioL , ZulianiF , CorazzaL , ScainiP , ZaniR , LenziM , et al. Rituximab monotherapy of severe HCV‐related cryoglobulinemic vasculitis for more than 2 years: follow‐up of a randomized controlled multicentre study [abstract no: OP0228]. Annals of the Rheumatic Diseases2014; Vol. 73. [EMBASE: 71551183] ">De Vita 2012</a>; <a href="./references#CD010965-bbs2-0042" title="GaltonC , DeemS , YanezND , SouterM , ChesnutR , DagalA , et al. Open‐label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury. Neurocritical Care2011;14(3):354‐60. [MEDLINE: 21409494] ">Galton 2011</a>; <a href="./references#CD010965-bbs2-0050" title="MoriT . Hypervolemic therapy with fludrocortisone acetate for brain protection from cerebral vasospasm caused by subarachnoid hemorrhage. Nihon University Journal of Medicine1999;41(1):39‐54. [EMBASE: 29149014] ">Mori 1999</a>; <a href="./references#CD010965-bbs2-0052" title="OwenBE , RogersIR , HoffmanMD , StuempfleKJ , LewisD , FogardK , et al. Efficacy of oral versus intravenous hypertonic saline in runners with hyponatremia. Journal of Science &amp; Medicine in Sport2014;17(5):457‐62. [MEDLINE: 24148616] ">Owen 2014</a>; <a href="./references#CD010965-bbs2-0055" title="RamsayF , CrawfordRJ , AllmanS , BaileyR , MartinA . An open comparative study of two diuretic combinations, frusemide/amiloride ('Frumil') and bumetanide/potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out‐patients. Current Medical Research &amp; Opinion1988;10(10):682‐9. [MEDLINE: 3371084] ">Ramsay 1988</a>; <a href="./references#CD010965-bbs2-0069" title="ZamboliP , DeNicolaL , MinutoloR , ChiodiniP , CrivaroM , TassinarioS , et al. Effect of furosemide on left ventricular mass in non‐dialysis chronic kidney disease patients: a randomized controlled trial. Nephrology Dialysis Transplantation2011;26(5):1575‐83. [MEDLINE: 20876366] ">Zamboli 2011</a>; <a href="./references#CD010965-bbs2-0070" title="ZellwegerM , SaudanP , SaudanM , HoffmeyerP , MartinP . Do COX‐2 inhibitors induce more hyponatremia than non‐selective NSAIDs? [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):141A. [CENTRAL: CN‐00448525] ">Zellweger 2001</a>), some participants possibly having hyponatraemia but without available subgroup data (<a href="./references#CD010965-bbs2-0036" title="AbrahamWT , ShamshirsazAA , McFannK , OrenRM , SchrierRW . Aquaretic effect of lixivaptan, an oral, non‐peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. Journal of the American College of Cardiology2006;47(8):1615‐21. [MEDLINE: 16630999] ">Abraham 2006</a>; <a href="./references#CD010965-bbs2-0039" title="AngeliP , FasolatoS , MazzaE , OkolicsanyiL , MaresioG , VeloE , et al. Combined versus sequential diuretic treatment of ascites in non‐azotaemic patients with cirrhosis: Results of an open randomised clinical trial. Gut2010;59(1):98‐104. [MEDLINE: 19570764] ">Angeli 2010</a>; <a href="./references#CD010965-bbs2-0043" title="GhaliJK , OrlandiC , AbrahamWT , CK‐LX2401 Study Investigators. The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group study. European Journal of Heart Failure2012;14(6):642‐51. [MEDLINE: 22510424] ">Ghali 2012</a>; <a href="./references#CD010965-bbs2-0045" title="GuyaderD , PatatA , Ellis‐GrosseEJ , OrczykGP . Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology2002;36(5):1197‐205. [MEDLINE: 12395330] ">Guyader 2002</a>; <a href="./references#CD010965-bbs2-0046" title="InomataT , IkedaY , KidaK , ShibagakiY , SatoN , KumagaiY , et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment‐ results from the K‐STAR study. Circulation Journal2017;82(1):159‐67. [MEDLINE: 28835586] InomataT , IkedaY , ShinagawaH , KidaK , ShibagakiY , SatoN , et al. Effect of additive tolvaptan versus increased furosemide on refractory heart failure with renal impairment: Results from the K‐STAR study [abstract no: P3742]. European Heart Journal2015;36(Suppl 1):659. [EMBASE: 72021230] TominagaN , KidaK , InomataT , SatoN , IzumiT , AkashiYJ , et al. Significance of serum sodium concentration in the very early treatment phase of congestive heart failure complicated by advanced chronic kidney disease: Posthoc analysis of the K‐STAR study [abstract]. Nephrology Dialysis Transplantation2016;31(Suppl 1):i175. [EMBASE: 72326366] ">K‐STAR 2017</a>; <a href="./references#CD010965-bbs2-0047" title="LicataG , DiPasqualeP , ParrinelloG , CardinaleA , ScandurraA , FolloneG , et al. Effects of high‐dose furosemide and small‐volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long‐term effects. American Heart Journal2003;145(3):459‐66. [MEDLINE: 12660669] ">Licata 2003</a>; <a href="./references#CD010965-bbs2-0048" title="MatsuzakiM , HoriM , IzumiT , AsanoiH , TsutamotoT . Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Cardiovascular Drugs &amp; Therapy2011;25 Suppl 1:S19‐31. [MEDLINE: 22120091] ">Matsuzaki 2011a</a>; <a href="./references#CD010965-bbs2-0049" title="MatsuzakiM , HoriM , IzumiT , FukunamiM . Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double‐blind, placebo‐controlled study (QUEST study). Cardiovascular Drugs &amp; Therapy2011;25 Suppl 1:S33‐45. [MEDLINE: 22120092] ">Matsuzaki 2011b</a>; <a href="./references#CD010965-bbs2-0051" title="OkitaK , KawazoeS , HasebeC , KajimuraK , KanekoA , OkadaM , et al. Dose‐finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double‐blind, placebo‐controlled trial. Hepatology Research2014;44(1):83‐91. [MEDLINE: 23530991] SakaidaI , NakajimaK , OkitaK , HoriM , IzumiT , SakuraiM , et al. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. Journal of Gastroenterology2015;50(10):1047‐53. [MEDLINE: 25689936] ">Okita 2014</a>; <a href="./references#CD010965-bbs2-0053" title="PaternaS , DiPasqualeP , ParrinelloG , AmatoP , CardinaleA , FolloneG , et al. Effects of high‐dose furosemide and small‐volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. European Journal of Heart Failure2000;2(3):305‐13. [MEDLINE: 10938493] ">Paterna 2000</a>; <a href="./references#CD010965-bbs2-0057" title="SakaidaI , KawazoeS , KajimuraK , SaitoT , OkuseC , TakaguchiK , et al. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double‐blind, placebo‐controlled trial. Hepatology Research2014;44(1):73‐82. [MEDLINE: 23551935] SakaidaI , NakajimaK , OkitaK , HoriM , IzumiT , SakuraiM , et al. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan. Journal of Gastroenterology2015;50(10):1047‐53. [MEDLINE: 25689936] ">Sakaida 2014</a>; <a href="./references#CD010965-bbs2-0059" title="FelkerGM , MentzRJ , AdamsKF , ColeRT , EgnaczykGF , PatelCB , et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circulation: Heart Failure2015;8(5):997‐1005. [MEDLINE: 26374918] KonstamMA , KiernanM , ChandlerA , DhingraR , ModyFV , EisenH , et al. Short‐term effects of tolvaptan in patients with acute heart failure and volume overload. Journal of the American College of Cardiology2017;69(11):1409‐19. [MEDLINE: 28302292] ">SECRET of CHF 2017</a>; <a href="./references#CD010965-bbs2-0060" title="ShanmugamE , DossCR , GeorgeM , JenaA , RajaramM , RamarajB , et al. Effect of tolvaptan on acute heart failure with hyponatremia ‐ a randomized, double blind, controlled clinical trial. Indian Heart Journal2016;68 Suppl 1:S15‐21. [MEDLINE: 27056648] ">Shanmugam 2016</a>; <a href="./references#CD010965-bbs2-0061" title="SuzukiS , YoshihisaA , AbeY , SaitoT , OhwadaT , KubotaI , et al. Acute heart failure volume control trial: The comparison of tolvaptan and carperitide [abstract]. European Heart Journal2013;34(Suppl 1):619. [EMBASE: 71259816] SuzukiS , YoshihisaA , YamakiT , SugimotoK , KuniiH , NakazatoK , et al. Acute Heart Failure Volume Control Multicenter Randomized (AVCMA) Trial: comparison of tolvaptan and carperitide. Journal of Clinical Pharmacology2013;53(12):1277‐85. [MEDLINE: 24142853] ">Suzuki 2013b</a>; <a href="./references#CD010965-bbs2-0062" title="KimuraK , MomoseT , HasegawaT , MoritaT , MisawaT , MotokiH , et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. Journal of Cardiology2016;67(5):399‐405. [MEDLINE: 26692119] ">TACT‐ADHF 2016</a>; <a href="./references#CD010965-bbs2-0063" title="FelkerGM , MentzRJ , AdamsKF , ColeRT , EgnaczykGF , PatelCB , et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circulation: Heart Failure2015;8(5):997‐1005. [MEDLINE: 26374918] FelkerGM , MentzRJ , ColeRT , AdamsKF , EgnaczykGF , FiuzatM , et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. Journal of the American College of Cardiology2017;69(11):1399‐406. [MEDLINE: 27654854] ">TACTICS‐HF 2017</a>; <a href="./references#CD010965-bbs2-0064" title="ThuluvathPJ , MaheshwariA , WongF , YooHW , SchrierRW , ParikhC , et al. Oral V2 receptor antagonist (RWJ‐351647) in patients with cirrhosis and ascites: a randomized, double‐blind, placebo‐controlled, single ascending dose study. Alimentary Pharmacology &amp; Therapeutics2006;24(6):973‐82. [MEDLINE: 16948809] ">Thuluvath 2006</a>; <a href="./references#CD010965-bbs2-0065" title="WongF , BernardiM , HorsmansY , CabrijanZ , WatsonH . Effects of Satavaptan, an oral vasopressin V2 receptor antagonist, on management of ascites and morbidity in liver cirrhosis in a long‐term, placebo‐controlled study [abstract]. Journal of Hepatology2009;50(Suppl 1):S42‐S43. [EMBASE: 70133362] ">Wong 2009</a>; <a href="./references#CD010965-bbs2-0066" title="WongF , GinesP , WatsonH , HorsmansY , AngeliP , GowP , et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. Journal of Hepatology2010;53(2):283‐90. [MEDLINE: 20541828] ">Wong 2010a</a>; <a href="./references#CD010965-bbs2-0067" title="WongF , WatsonH , GerbesA , VilstrupH , BadalamentiS , BernardiM , et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut2012;61(1):108‐16. [MEDLINE: 21836029] ">Wong 2012</a>; <a href="./references#CD010965-bbs2-0068" title="YangYY , LinHC , LeeWP , ChuCJ , LinMW , LeeFY , et al. Association of the G‐protein and alpha2‐adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial. Gut2010;59(11):1545‐53. [MEDLINE: 20833658] ">Yang 2010b</a>); having hyponatraemia but caused by psychogenic polydipsia (<a href="./references#CD010965-bbs2-0038" title="AlexanderRC , KarpBI , ThompsonS , KhotV , KirchDG . A double blind, placebo‐controlled trial of demeclocycline treatment of polydipsia‐hyponatremia in chronically psychotic patients. Biological Psychiatry1991;30(4):417‐20. [MEDLINE: 1912134] ">Alexander 1991</a>), prolonged exercise (<a href="./references#CD010965-bbs2-0056" title="RogersIR , HookG , StuempfleKJ , HoffmanMD , Hew‐ButlerT . An intervention study of oral versus intravenous hypertonic saline administration in ultramarathon runners with exercise‐associated hyponatremia: a preliminary randomized trial. Clinical Journal of Sport Medicine2011;21(3):200‐3. [MEDLINE: 21519296] ">Rogers 2011</a>), or head and neck surgery (<a href="./references#CD010965-bbs2-0054" title="RajanS , SrikumarS , PaulJ , KumarL . Effectiveness of single dose conivaptan for correction of hyponatraemia in post‐operative patients following major head and neck surgeries. Indian Journal of Anaesthesia2015;59(7):416‐20. [MEDLINE: 26257414] ">Rajan 2015</a>); or having severe symptoms requiring immediate treatment <a href="./references#CD010965-bbs2-0058" title="LeeA , JoYH , KimK , AhnS , OhYK , LeeH , et al. Efficacy and safety of rapid intermittent correction compared with slow continuous correction with hypertonic saline in patients with moderately severe or severe symptomatic hyponatremia: study protocol for a randomized controlled trial (SALSA trial). Trials [Electronic Resource]2017;18(1):147. [MEDLINE: 28356136] ">SALSA 2017</a>). One study compared two different salt‐restricted diets in combination with step‐wise increase of diuretic treatment for reducing weight and ascites in patients with decompensated liver cirrhosis (<a href="./references#CD010965-bbs2-0040" title="BernardiM , LaffiG , SalvagniniM , AzzenaG , BonatoS , MarraF , et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver1993;13(3):156‐62. [MEDLINE: 8336527] ">Bernardi 1993</a>); and finally one study (<a href="./references#CD010965-bbs2-0044" title="GinesP , WongF , WatsonH . Long‐term improvement of serum sodium by the V2‐receptor antagonist satavaptan in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2007;46(Suppl 1):S41. [CENTRAL: CN‐00653239] ">Gines 2007</a>) would have led to double counting of participants as it represented a second randomised trial built on top of a first included study (<a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>) using the same study medication. </p> </section> </section> <section id="CD010965-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias is described in (<a href="#CD010965-fig-0002">Figure 2</a>; <a href="#CD010965-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD010965-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010965-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010965-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010965-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010965-sec-0068"> <h4 class="title">Allocation</h4> <p>The allocation sequence was adequately generated in 14 studies (<a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>). and adequately concealed in 12 studies (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>). For the remaining studies the authors provided insufficient information about the procedures to permit a judgement of the risk of bias. </p> </section> <section id="CD010965-sec-0069"> <h4 class="title">Blinding</h4> <p>In 26 studies, all assessing a vasopressin receptor antagonist, the investigators attempted to blind participants and personnel by providing a matching placebo (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>). Although it was probably unlikely for participants and personnel to be fully blinded due to important increases in urine output when treated with a vasopressin receptor antagonist, co‐interventions of fluid restriction or salt‐intake were reported and similar in 12 studies (<a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>). For two studies, fluid restriction could be adapted by both participant and treating physician (e.g. based on urine output). We judged this would not have introduced important risk of bias for death and objective outcomes related to serum sodium concentration, but may have biased health‐related quality of life measures and resulted in biased estimates of risk of rapid increase in serum sodium concentration (<a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>). </p> <p>Three studies explicitly reported blinding of outcomes assessors (<a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>). In 28 others we judged blinding of outcome assessors would likely have occurred or measured outcomes were objective enough so that the risk of bias was probably low (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0006" title="DzauVJ , HollenbergNK . Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine1984;100(6):777‐82. [MEDLINE: 6372563] ">Dzau 1984</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0011" title="GheorghiadeM , GottliebSS , UdelsonJE , KonstamMA , CzerwiecF , OuyangJ , et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. American Journal of Cardiology2006;97(7):1064‐7. [MEDLINE: 16563917] ">Gheorghiade 2006</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a>; <a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>). </p> </section> <section id="CD010965-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>In 17 studies, attrition stayed below 20% with either well documented reasons and/or limited opportunity for important bias (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0006" title="DzauVJ , HollenbergNK . Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine1984;100(6):777‐82. [MEDLINE: 6372563] ">Dzau 1984</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0011" title="GheorghiadeM , GottliebSS , UdelsonJE , KonstamMA , CzerwiecF , OuyangJ , et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. American Journal of Cardiology2006;97(7):1064‐7. [MEDLINE: 16563917] ">Gheorghiade 2006</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>). Eight studies had attrition rates &gt; 25% and either did not attempt to re‐include participants in the analysis (<a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a><a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>) or used imputation methods to deal with missing serum sodium concentration values that may have caused overestimation of the effect of the study medication ‐ e.g. last observation carried forward, thus ignoring rebound hyponatraemia on cessation of treatment (<a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>). The others provided insufficient information to allow judgement of high or low risk of bias (<a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0014" title="HayesPC , WilliamsR . Oral urea in the treatment of hyponatraemic ascites [abstract]. Gut1987;28(10):A1386. [CENTRAL: CN‐00221198] ">Hayes 1987</a>; <a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0034" title="YangP . Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]. Heart2013;99(Suppl 3):A221. [EMBASE: 71317230] ">Yang 2013</a>). </p> </section> <section id="CD010965-sec-0071"> <h4 class="title">Selective reporting</h4> <p>For 15 studies, we found a registered protocol in a trial registry (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>). The Otsuka Study was registered as a single study but reported was as three separate studies (<a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>). Investigators fully reported all expected pre‐registered outcomes at pre‐registered time‐points in two studies (<a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>). Whether a protocol was provided or not, for 12 studies investigators reported all expected outcomes related to benefit and harms at reasonable time‐points (<a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>; <a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>). In seven studies with treatment duration &gt; one week, authors did not report the primary outcomes all‐cause mortality or health‐related quality of life or any outcome related to rapid increases in serum sodium concentration (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0034" title="YangP . Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]. Heart2013;99(Suppl 3):A221. [EMBASE: 71317230] ">Yang 2013</a>). In eight studies with treatment duration ≤ 1 week, authors did not report any secondary outcome related to serum sodium concentration or rapid increases thereof (<a href="./references#CD010965-bbs2-0006" title="DzauVJ , HollenbergNK . Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine1984;100(6):777‐82. [MEDLINE: 6372563] ">Dzau 1984</a>; <a href="./references#CD010965-bbs2-0011" title="GheorghiadeM , GottliebSS , UdelsonJE , KonstamMA , CzerwiecF , OuyangJ , et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. American Journal of Cardiology2006;97(7):1064‐7. [MEDLINE: 16563917] ">Gheorghiade 2006</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>). </p> </section> <section id="CD010965-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <section id="CD010965-sec-0073"> <h5 class="title">Bias through possible financial conflict of interest of the authors, sponsorship bias, or both </h5> <p>Industry funded 28 studies (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0004" title="DecauxG , SoupartA , FintaE , AlfoldiS . Randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F‐FC007]. Journal of the American Society of Nephrology2006;17(Abstracts):38A. ">Decaux 2006</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0011" title="GheorghiadeM , GottliebSS , UdelsonJE , KonstamMA , CzerwiecF , OuyangJ , et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. American Journal of Cardiology2006;97(7):1064‐7. [MEDLINE: 16563917] ">Gheorghiade 2006</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0024" title="ChenS , ZhaoJJ , TongNW , GuoXH , QiuMC , YangGY , et al. Randomized, double blinded, placebo‐controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH. Journal of Clinical Pharmacology2014;54(12):1362‐7. [MEDLINE: 24906029] ">Otsuka Study 2011a</a>; <a href="./references#CD010965-bbs2-0025" title="LiL , BaiH , ZhuWL , Tolvaptan Therapy in Hyponatremia with Heart Failure Collaborative Group. The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]2011;39(10):936‐40. [MEDLINE: 22321279] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0446]. Heart2011;97(Suppl 3):A127. [EMBASE: 70739844] LingL , WenlingZ , HuaB . The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22‐e0831]. Heart2011;97(Suppl 3):A216‐7. [EMBASE: 70740110] ">Otsuka Study 2011b</a>; <a href="./references#CD010965-bbs2-0026" title="JiaJ , WangHF , ChengW , YeW , DingH , DengC . A multicenter, randomized, double‐blind, placebo‐controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]. Journal of Hepatology2012;56(Suppl 2):S249. [CENTRAL: CN‐00844257] ">Otsuka Study 2011c</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0032" title="SoupartA , GrossP , LegrosJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2‐receptor antagonist [abstract no: SU‐PO0140]. Journal of the American Society of Nephrology2004;15(Oct):563A. [CENTRAL: CN‐00583147] SoupartA , GrossP , LegrosJJ , AlfoldiS , AnnaneD , HeshmatiHM , et al. Successful long‐term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2‐receptor antagonist. Clinical Journal of the American Society of Nephrology: CJASN2006;1(6):1154‐60. [MEDLINE: 17699341] ">Soupart 2006</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>). The funding source was unclear for six studies (<a href="./references#CD010965-bbs2-0006" title="DzauVJ , HollenbergNK . Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine1984;100(6):777‐82. [MEDLINE: 6372563] ">Dzau 1984</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a>; <a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a>; <a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a>; <a href="./references#CD010965-bbs2-0034" title="YangP . Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]. Heart2013;99(Suppl 3):A221. [EMBASE: 71317230] ">Yang 2013</a>). For 17 studies we retrieved a declaration of interest for the authors featuring on the reports (<a href="./references#CD010965-bbs2-0001" title="GheorghiadeM , GattisWA , BarbagelataA , AdamsKFJr , ElkayamU , OrlandiC , et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. American Heart Journal2003;145(2 Suppl):S51‐4. [MEDLINE: 12594452] GheorghiadeM , GattisWA , O'ConnorCM , AdamsKFJr , ElkayamU , BarbagelataA , et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA2004;291(16):1963‐71. [MEDLINE: 15113814] RossiJ , BayramM , UdelsonJE , Lloyd‐JonesD , AdamsKF , OconnorCM , et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Cardiac Care2007;9(2):82‐6. [MEDLINE: 17573581] ">ACTIV in CHF 2003</a>; <a href="./references#CD010965-bbs2-0002" title="AnnaneD , DecauxG , SmithN , Conivaptan Study Group. Efficacy and safety of oral conivaptan, a vasopressin‐receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. American Journal of the Medical Sciences2009;337(1):28‐36. [MEDLINE: 19057376] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GrossP , BisahaJG , SmithN . Conivaptan, a novel V1a/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA‐PO243]. Journal of the American Society of Nephrology2004;15(Oct):353A. ">Annane 2009</a>; <a href="./references#CD010965-bbs2-0005" title="AronsonD , MuellerM , VerbalisJ , KrumH , DILIPO Investigators. Satavaptan, a vasopressin V2‐receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU‐PO928]. Journal of the American Society of Nephrology2007;18(Abstracts):790A. AronsonD , VerbalisJG , MuellerM , KrumH , DILIPO investigators. Short‐ and long‐term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2‐receptor antagonist: the DILIPO study. European Journal of Heart Failure2011;13(3):327‐36. [MEDLINE: 21199833] ">DILIPO 2011</a>; <a href="./references#CD010965-bbs2-0007" title="AllenLA , GheorghiadeM , ReidKJ , DunlaySM , ChanPS , HauptmanPJ , et al. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circulation. Cardiovascular Quality &amp; Outcomes2011;4(4):389‐98. [MEDLINE: 21693723] AmbrosyAP , VaduganathanM , MentzRJ , GreeneSJ , SubaciusH , KonstamMA , et al. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. American Heart Journal2013;165(2):216‐25. [MEDLINE: 23351825] BlairJE , ZannadF , KonstamMA , CookT , TraverB , BurnettJCJr , et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. Journal of the American College of Cardiology2008;52(20):1640‐8. [MEDLINE: 18992654] ChiongJR , KimS , LinJ , ChristianR , DastaJF . Evaluation of costs associated with tolvaptan‐mediated length‐of‐stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. Journal of Medical Economics2012;15(2):276‐84. [MEDLINE: 22111754] CyrPL , SlawskyKA , OlchanskiN , KrasaHB , GossTF , ZimmerC , et al. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. American Journal of Health‐System Pharmacy2011;68(4):328‐33. [MEDLINE: 21289328] DastaJ , ChiongJ , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]. Pharmacotherapy2011;31(10):370e. [EMBASE: 70648093] DastaJF , ChiongJR , KimS , LinJ . Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]. Value in Health2011;14(3):A38‐9. [EMBASE: 70490649] GheorghiadeM , KonstamMA , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Short‐term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA2007;297(12):1332‐43. [MEDLINE: 17384438] GheorghiadeM , OrlandiC , BurnettJC , DemetsD , GrinfeldL , MaggioniA , et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). Journal of Cardiac Failure2005;11(4):260‐9. [MEDLINE: 15880334] HauptmanPJ , BurnettJ , GheorghiadeM , GrinfeldL , KonstamMA , KosticD , et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. Journal of Cardiac Failure2013;19(6):390‐7. [MEDLINE: 23743487] KonstamMA , GheorghiadeM , BurnettJCJr , GrinfeldL , MaggioniAP , SwedbergK , et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA2007;297(12):1319‐31. [MEDLINE: 17384437] MentzRJ , GreeneSJ , AmbrosyAP , VaduganathanM , SubaciusHP , SwedbergK , et al. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circulation: Heart Failure2014;7(3):401‐8. [MEDLINE: 24737459] O'ConnorCM , MillerAB , BlairJE , KonstamMA , WedgeP , BahitMC , et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]. American Heart Journal2010;159(5):841‐9. [MEDLINE: 20435194] PangPS , GheorghiadeM , DihuJ , SwedbergK , KhanS , MaggioniAP , et al. Effects of tolvaptan on physician‐assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. American Heart Journal2011;161(6):1067‐72. [MEDLINE: 21641352] VaduganathanM , GheorghiadeM , PangPS , KonstamMA , ZannadF , SwedbergK , et al. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine2012;13(7):415‐22. [MEDLINE: 22673023] ">EVEREST 2005</a>; <a href="./references#CD010965-bbs2-0009" title="GhaliJK , KorenMJ , TaylorJR , Brooks‐AsplundE , FanK , LongWA , et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo‐controlled trial in patients with euvolemic or hypervolemic hyponatremia. Journal of Clinical Endocrinology &amp; Metabolism2006;91(6):2145‐52. [MEDLINE: 16522696] GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] ">Ghali 2006</a>; <a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0008" title="DecauxG , HannotierP , PennickxR , SoupartA , DjianJ . Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Abstracts):120A. [CENTRAL: CN‐00550692] GerbesAL , GulbergV , GinèsP , DecauxG , GrossP , GandjiniH , et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double‐blind multicenter trial. Gastroenterology2003;124(4):933‐9. [MEDLINE: 12671890] GrossP , DecauxG , GerbesA , DjianJ . Treatment of hyponatremia (hypo) with VPA‐985 [abstract]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):121A. GuelbergGV , DecauxG , GrossP , MassienC , DjianJ . VPA‐985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double‐blind placebo controlled multicenter trial [abstract]. Hepatology1999;30(4):419A. [CENTRAL: CN‐00280911] ">Gerbes 2003</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a>; <a href="./references#CD010965-bbs2-0019" title="KorenMJ , HamadA , KlasenS , AbeyratneA , McNuttBE , KalraS . Efficacy and safety of 30‐minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]. American Journal of Health‐System Pharmacy2011;68(9):818‐27. [MEDLINE: 21515866] ">Koren 2011</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>; <a href="./references#CD010965-bbs2-0028" title="BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA , et al. The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467A‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐1 2006</a>; <a href="./references#CD010965-bbs2-0029" title="AfdhalN , CardenasA , GinesP , GrossP , VerbalisJ , BerlT . Randomized, placebo‐controlled trial of tolvaptan, a novel v2‐receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]. Hepatology2005;42(Suppl 1):756A. [CENTRAL: CN‐00581716] BaiS , TargumS , ThompsonA . Combined clinical and statistical review. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐02.pdf (accessed 18 January 2018):1‐120. BerlT , Quittnat‐PelletierF , VerbalisJG , SchrierRW , BichetDG , OuyangJ , et al. Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]. Journal of the American Society of Nephrology2010;21(4):705‐12. [MEDLINE: 20185637] BlaisJ , AhmadF , ChiodoJ , GlaserLA , GrallaRJ , ZhouW , et al. Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post‐hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]. Supportive Care in Cancer2014;22(1 Suppl 1):S156‐7. [EMBASE: 71501979] CardenasA , GinesP , MarottaP , CzerwiecF , OyuangJ , GuevaraM , et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology2012;56(3):571‐8. [MEDLINE: 22027579] CardenasA , GinesP , MarottaP , CzerwiecFS , OuyangJ , SextonA . The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]. Hepatology2009;50(Suppl 4):467‐8A. [CENTRAL: CN‐00739662] DastaJ , ChiongJ , ChristianR , LinJ . Estimation of cost savings associated with tolvaptan‐mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT‐1 and SALT‐2 trials [abstract no: 563]. Critical Care Medicine2011;39(Suppl 12):155. [EMBASE: 71058874] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT‐1 and SALT‐2 trials [abstract]. Value in Health2012;15(4):A176. [EMBASE: 70763929] DastaJF , ChiongJR , ChristianR , LinJ . Evaluation of costs associated with tolvaptan‐mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT‐1 and SALT‐2 trials. Hospital Practice (1995)2012;40(1):7‐14. [MEDLINE: 22406878] JosiassenRC , GoldmanM , JessaniM , ShaughnessyRA , AlbazzazA , LeeJ , et al. Double‐blind, placebo‐controlled, multicenter trial of a vasopressin V2‐receptor antagonist in patients with schizophrenia and hyponatremia. Biological Psychiatry2008;64(12):1097‐100. [MEDLINE: 18692175] Otsuka Pharmaceutical Development &amp; Commercialization. Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐05.pdf (accessed 18 January 2018):1‐131. SchrierRW , GrossP , GheorghiadeM , BerlT , VerbalisJG , CzerwiecFS , et al. Tolvaptan, a selective oral vasopressin V2‐receptor antagonist, for hyponatremia. New England Journal of Medicine2006;355(20):2099‐112. [MEDLINE: 17105757] TruemanD , HancockE , RobinsonP , DaleP , O'ReillyK , GisbyM . EQ‐5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]. Value in Health2014;17(7):A354. [MEDLINE: 27200696] TruemanD , RobinsonP , DaleP , O'ReillyK , LundbergJ , JamookeeahC . The cost‐effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]. Value in Health2014;17(7):A350. [MEDLINE: 27200675] U.S.Food , DrugAdministration . NDA 22‐275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient‐reported outcome (PRO) measures for the hyponatremia indication. www.fda.gov/ohrms/dockets/ac/08/briefing/2008‐4373b1‐03.pdf (accessed 18 January 2018):1‐7. VerbalisJG , AdlerS , SchrierRW , BerlT , ZhaoQ , CzerwiecFS , et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology2011;164(5):725‐32. [MEDLINE: 21317283] ">SALT‐2 2006</a>; <a href="./references#CD010965-bbs2-0035" title="GhaliJK , VerbalisJG , GrossP , LongWA , SmithN . Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F‐FC028]. Journal of the American Society of Nephrology2005;16(Abstracts):43A. [CENTRAL: CN‐00677109] GoldsmithSR , VerbalisJG , BarveA , AndohM . Efficacy and safety of the vasopressin‐receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU‐PO929]. Journal of the American Society of Nephrology2007;18(Abstracts Issue):790A. VerbalisJG , BisahaJG , SmithN . Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA‐PO254]. Journal of the American Society of Nephrology2004;15(Abstracts):356A. VerbalisJG , GhaliJK , GrossP , LongWA , SmithN . Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]. Journal of Clinical Oncology2006;24(18 Suppl):480. [CENTRAL: CN‐00616898] VerbalisJG , RosanskyS , WagonerLE , McNuttB , YanB . Efficacy and safety of conivaptan, a vasopressin v1a‐ and v2‐receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]. Chest2007;132(4 Suppl):562S. [CENTRAL: CN‐00645592] VerbalisJG , ZeltserD , SmithN , BarveA , AndohM . Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clinical Endocrinology2008;69(1):159‐68. [MEDLINE: 18034777] ZeltserD , RosanskyS , vanRensburgH , VerbalisJG , SmithN , Conivaptan Study Group. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. American Journal of Nephrology2007;27(5):447‐57. [MEDLINE: 17664863] ">Zeltser 2007</a>). All save one (<a href="./references#CD010965-bbs2-0021" title="NaidechAM , PaparelloJ , LieblingSM , BassinSL , LevasseurK , AlbertsMJ , et al. Use of Conivaptan (Vaprisol) for hyponatremic neuro‐ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]. Neurocritical Care2010;13(1):57‐61. [MEDLINE: 20568023] ">Naidech 2010</a>) had author lists who featured people who had received money for presentations or consultancy, or were employed by the sponsor. </p> </section> </section> </section> <section id="CD010965-sec-0074"> <h3 class="title" id="CD010965-sec-0074">Effects of interventions</h3> <p>See: <a href="./full#CD010965-tbl-0001"><b>Summary of findings for the main comparison</b> Vasopressin receptor antagonists versus placebo or no treatment for chronic non‐hypovolaemic hypotonic hyponatraemia</a> </p> <section id="CD010965-sec-0075"> <h4 class="title">Vasopressin receptor antagonists versus placebo or no treatment</h4> <section id="CD010965-sec-0076"> <h5 class="title">Primary outcomes</h5> <p>Vasopressin receptor antagonists had uncertain effects on mortality, results being compatible with both 11 in 1000 fewer to 47 in 1000 more deaths within six months (<a href="./references#CD010965-fig-0007" title="">Analysis 1.1</a> (15 studies, 2330 participants): RR 1.11, 95% CI 0.92 to 1.33; I<sup>2</sup> = 0%). Using GRADE criteria, we downgraded the certainty of the evidence three levels from high to very low, partly because of this imprecision, partly for a risk of selective reporting (<a href="./references#CD010965-bbs2-0078" title="GuyattGH , OxmanAD , SchünemannHJ , TugwellP , KnottnerusA . GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2010;64:380‐382. [MEDLINE: 21185693] ">Guyatt 2010</a>). Six of 16 long‐term studies reasonably expected to measure death as an outcome did not, and the absence of a protocol did not allow to assess whether its measurement may have been planned, but not reported (<a href="./references#CD010965-bbs2-0010" title="GheorghiadeM , NiaziI , OuyangJ , CzerwiecF , KambayashiJ , ZampinoM , et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation2003;107(21):2690‐6. [MEDLINE: 12742979] ">Gheorghiade 2003</a>; <a href="./references#CD010965-bbs2-0012" title="GinesP , WongF , MartinM , LecorpsG , WatsonHR . Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long‐term placebo‐controlled study [abstract]. Hepatology2008;48(Suppl 4):413A‐4A. [CENTRAL: CN‐00690109] ">Gines 2008b</a>; <a href="./references#CD010965-bbs2-0015" title="CordobaJ , GuevaraM , WatsonHR , GuennecS , GinesP . Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]. Hepatology2009;50(Suppl 4):451A‐2A. [CENTRAL: CN‐00739727] GinesP , WongF , MilutinovicS , delArbolLR , OlteanuD . Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]. Journal of Hepatology2006;44(Suppl 2):S270. [CENTRAL: CN‐00581518] GinesP , WongF , WatsonH , MilutinovicS , delArbolLR , OlteanuD , et al. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology2008;48(1):204‐13. [MEDLINE: 18508290] ">HYPOCAT 2008</a>; <a href="./references#CD010965-bbs2-0023" title="NevensF , MorenoC , CoolsM , ThielemansL , KerstensR , MeulemansA . Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]. Journal of Hepatology2009;50(Suppl 1):S76. [CENTRAL: CN‐00715780] ">Nevens 2009</a>; <a href="./references#CD010965-bbs2-0033" title="WongF , BleiAT , BlendisLM , ThuluvathPJ . A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo‐controlled trial. Hepatology2003;37(1):182‐91. [MEDLINE: 12500203] ">Wong 2003b</a>; <a href="./references#CD010965-bbs2-0034" title="YangP . Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]. Heart2013;99(Suppl 3):A221. [EMBASE: 71317230] ">Yang 2013</a>). </p> <p>Vasopressin receptor antagonists increased scores for the mental component summary of the SF‐12 (<a href="./references#CD010965-fig-0008" title="">Analysis 1.2</a>.1 (2 studies, 297 participants): MD 4.76, 95% CI 0.11 to 9.41, I<sup>2</sup> = 63%), but had unclear effects on the physical component summary score (<a href="./references#CD010965-fig-0008" title="">Analysis 1.2</a>.2 (2 studies, 297 participants): MD 1.04, 95% CI ‐1.81 to 3.90, I<sup>2</sup> = 0%). We downgraded the certainty of the evidence for these outcomes one level because we judged the results to be at serious risk of performance bias due to likely unblinding of the participants with a self‐reported outcome; of selective reporting bias due to outcomes being measured at two different time‐points with only one time‐point reported; of attrition bias due to more than one third of the overall data being missing. We downgraded two additional levels for imprecision and indirectness, because of concerns around the validity of the SF‐12 for measuring quality of life in the context of hyponatraemia. </p> <p>Five studies evaluated cognitive function (<a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0013" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed on 28 June 2018):1‐217. AbrahamWT , DecauxG , JosiassenRC , YagilY , KopytN , ThackerHP , et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International2012;82(11):1215‐22. [MEDLINE: 22932122] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">HARMONY 2012</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>; <a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>; <a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>). In three studies, two of which provided data that could reliably contribute to meta‐analysis ((<a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>; <a href="./references#CD010965-bbs2-0020" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. news.medlive.cn/uploadfile/2012/0523/20120523095216110.pdf (accessed on 5 March 2018):1‐217. AbrahamW , JosiassenR , BichetDG , OrlandiC . Safety and efficacy of the vasopressin V2‐receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB‐PO3144]. Journal of the American Society of Nephrology2011;22(Abstracts):3B. AbrahamWT , HensenJ , GrossPA , BichetDG , JosiassenRC , ChafekarDS , et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International2012;82(11):1223‐30. [MEDLINE: 22932119] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM318869.pdf (accessed on 15 March 2015):1‐61. FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm345074.pdf (accessed on 15 March 2015):1‐203. ">LIBRA 2012</a>), investigators used the trail making test part B, a neuropsychological test of visual attention and task switching. They found lixivaptan did not shorten the time to complete the test (<a href="./references#CD010965-fig-0009" title="">Analysis 1.3</a> (858 participants): MD 6.89 sec, 95% CI ‐6.34 to 20.12). A fourth study tested reaction time, psychomotor and processing speeds and found no difference in change between the groups (<a href="./references#CD010965-bbs2-0016" title="VerbalisJG , EllisonH , HobartM , KrasaH , OuyangJ , CzerwiecFS , et al. Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT). American Journal of Kidney Diseases2016;67(6):893‐901. [MEDLINE: 26874645] ">INSIGHT 2016</a>, 56 participants, 0.20, 95% CI ‐0.10 to 0.50). The fifth study, assessing the change in mini mental state exam with tolvaptan, found no change from baseline (<a href="./references#CD010965-bbs2-0027" title="AliN , PallaS , GeorgeM , SalahudeenA . A randomized, double blind, placebo‐controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]. Journal of Investigative Medicine2013;61(2):501. [EMBASE: 70993379] SalahudeenAK , AliN , GeorgeM , LahotiA , PallaS . Tolvaptan in hospitalized cancer patients with hyponatremia: a double‐blind, randomized, placebo‐controlled clinical trial on efficacy and safety. Cancer2014;120(5):744‐51. [MEDLINE: 24895288] ">Salahudeen 2014</a>, 30 participants, MD ‐0.70, 95% CI ‐2.23, 0.83). We considered the evidence of moderate certainty, downgrading one level mainly because of some indirectness and imprecision as it is unclear to what extent the used tools reflect the impairment thought to be caused by hyponatraemia, and the outcome was infrequently studied. </p> <p>Three studies found vasopressin receptor antagonists shortened hospital stay anywhere between 0.3 and 3 days (<a href="./references#CD010965-fig-0010" title="">Analysis 1.4</a> (3 studies, 610 participants): MD ‐1.63 days, 95% CI ‐2.96 to ‐0.30, I<sup>2</sup> = 0%). We downgraded the certainty of the evidence one level because we judged it at serious risk of suffering from performance bias, as participants and personnel were likely unblinded due to polyuria as a side‐effect and this could have influenced self‐reported and professional appreciation of clinical condition and so have influenced decision to discharge from hospital. We downgraded an additional level for imprecision as the confidence interval of the pooled effect included both a negligible effect and a clinically important one. </p> </section> <section id="CD010965-sec-0077"> <h5 class="title">Secondary outcomes</h5> <p>Vasopressin receptor antagonists caused a modest increase in serum sodium concentration. At the end of treatment, participants treated with placebo had an average increase in serum sodium concentration ranging from 0.5 to 4.7 mmol/L. In comparison, people treated with a vasopressin receptor antagonist had an average increase that was approximately 4 mmol/L higher (<a href="./references#CD010965-fig-0011" title="">Analysis 1.5</a> (21 studies, 2641 participants): MD 4.17 mmol/L, 95% CI 3.18 to 5.16; I<sup>2</sup> = 91%). These results were generally consistent for studies with shorter and longer follow‐up. Although there was substantial heterogeneity among included studies as described by the I<sup>2</sup>, individual point estimates all favoured vasopressin receptor antagonists. Investigators often also analysed serum sodium concentration as a dichotomous outcome, defining response as an increase of 5 to 6 mmol/L or normalisation of the absolute value. Defined as such, the previous data translated into two and a half as many people having a response with vasopressin receptor antagonists compared with placebo (<a href="./references#CD010965-fig-0012" title="">Analysis 1.6</a> (18 studies, 2104 participants): RR 2.49, 95% CI 1.95 to 3.18; I<sup>2</sup> = 56%). On average 23% of participants treated with placebo had a response versus 57% treated with a vasopressin receptor antagonist. Overall, in absolute terms this implies treating three adults with hyponatraemia with a vasopressin receptor antagonist could result in one more individual attaining an increase in serum sodium concentration of 5 mmol/L. We downgraded the certainty of the evidence from high to moderate because in 7/21 studies, accounting for 53% of the total number of participants in those studies, we harboured serious concerns around attrition bias; either because outcomes were not measured in the participants that dropped out, or because analytic techniques were used that included all measurements of serum sodium concentration included until patient attrition, both of which we judged would likely have overestimated the treatment effect. </p> <p>Treatment with a vasopressin receptor antagonist raised the risk of rapid increases in serum sodium concentration by 67%, resulting in three additional people with a rapid increase per 100 treated with a vasopressin receptor antagonist versus placebo (<a href="./references#CD010965-fig-0013" title="">Analysis 1.7</a> (14 studies, 2058 participants): RR 1.67, 95% CI 1.16 to 2.40; I<sup>2</sup> = 0%). The analysis showed no significant heterogeneity. Additional sensitivity analysis including only studies defining an increase in serum sodium concentration of &gt; 12 mmol/L/24 h did not meaningfully change the results (<a href="./references#CD010965-fig-0020" title="">Analysis 1.14</a>.2 (10 studies, 1801 participants): RR 1.63, 95% CI 1.09 to 2.43; I<sup>2</sup> = 0%).The effects for hypernatraemia were unclear (<a href="./references#CD010965-fig-0014" title="">Analysis 1.8</a> (10 studies, 1595 participants): RR 1.37, 95% CI 0.63 to 3.01; I<sup>2</sup> = 1%). None of the included studies reported participants developing osmotic demyelination syndrome. For similar concerns related to attrition bias as, we considered the evidence to be of moderate certainty. </p> <p>Overall, treatment with vasopressin receptor antagonists increased the odds for thirst nearly three times compared versus treatment with placebo (<a href="./references#CD010965-fig-0015" title="">Analysis 1.9</a> (13 studies, 1666 participants): OR 2.77, 95% CI 1.80 to 4.27; I<sup>2</sup> = 66%). Other side‐effects were generally less extensively reported. Nevertheless there was some evidence vasopressin receptor antagonists substantially increased the risk of polyuria (<a href="./references#CD010965-fig-0016" title="">Analysis 1.10</a>.1 (6 studies, 1272 participants): RR 4.69, 95% CI 1.59 to 13.85, I<sup>2</sup> = 0%). The risk remained uncertain for hypotension (<a href="./references#CD010965-fig-0016" title="">Analysis 1.10</a>.2 (14 studies, 1748 participants): RR 1.11, 95% CI 0.75 to 1.63; I<sup>2</sup> = 0%), AKI (<a href="./references#CD010965-fig-0016" title="">Analysis 1.10</a>.3 (8 studies, 1920 participants): RR 0.89, 95% CI 0.67 to 1.18; I<sup>2</sup> = 0%), and liver function abnormalities (<a href="./references#CD010965-fig-0016" title="">Analysis 1.10</a>.4 (3 studies, 811 participants): RR 2.43, 95% CI 0.88 to 6.70; I<sup>2</sup> = 0%). Half of the studies in which the vasopressin receptor antagonist was administered intravenously evaluated important adverse events related to the infusion itself. Overall there were almost three times as many patients developing infusion‐site phlebitis (<a href="./references#CD010965-fig-0017" title="">Analysis 1.11</a>.2 (2 studies, 133 participants: RR 3.52, 95% CI 1.00 to 12.41; I<sup>2</sup> = 0%); the effects for infusion‐site thrombosis were less clear (<a href="./references#CD010965-fig-0017" title="">Analysis 1.11</a>.3 (2 studies, 133 participants): RR 1.75, 95% CI 0.21 to 14.80; I<sup>2</sup> = 0%). There were slightly fewer people who discontinued treatment when given placebo than when given a vasopressin receptor antagonist (<a href="./references#CD010965-fig-0018" title="">Analysis 1.12</a> (14 studies, 2429 participants): RR 0.93, 95% CI 0.85 to 1.00; I<sup>2</sup> = 0%). </p> </section> <section id="CD010965-sec-0078"> <h5 class="title">Analysis of heterogeneity</h5> <p>Using univariate meta‐regression and subgroup analyses, we explored possible sources of heterogeneity in the effect of vasopressin receptor antagonists on the change in serum sodium concentration. Our prespecified potential sources were: the specific vasopressin receptor antagonist compound, the underlying condition causing the hyponatraemia (with as non‐prespecified categories studies only including participants with inappropriate antidiuresis; studies only including participants with heart failure or liver cirrhosis or studies including both), mean baseline serum sodium concentration, treatment duration and risk of selection bias as sources of heterogeneity. A higher serum sodium concentration at baseline resulted in smaller increases in serum sodium with treatment (<a href="#CD010965-fig-0004">Figure 4</a>). Per 1 mmol/L increase in baseline serum sodium concentration between 124 and 133 mmol/L, the mean difference on average decreased from 5.7 by 0.33 mmol/L (95% CI ‐0.89 to ‐0.60) to 2.7 mmol/L (<a href="#CD010965-tbl-0002">Table 1</a>). There was no evidence that the compound, the cause of hyponatraemia, the treatment duration or risk of selection bias modified the effect of vasopressin receptor antagonists on change from baseline in serum sodium concentration. </p> <div class="figure" id="CD010965-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Effect of baseline serum sodium concentration on change in natraemia: meta‐regression" data-id="CD010965-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Effect of baseline serum sodium concentration on change in natraemia: meta‐regression</p> </div> </div> </div> <div class="table" id="CD010965-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Change in serum sodium concentration: meta‐regression and confounding</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Covariate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies included in meta‐regression</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Absolute change in mean difference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline serum sodium concentration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per 1 mmol/L increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33 (‐0.65 to ‐0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Compound</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative to conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.79 (‐5.47 to ‐0.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Satavaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0,23 (‐3.34 to 2.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.82 (‐3.13 to 1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Cause of hyponatraemia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative to SIADH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIADH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combined SIADH ‐ Heart failure, cirrhosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (‐1.77 to 3.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.19 (‐3.84 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Treatment duration</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per day increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.02 (‐0,04 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Risk of selection bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative to low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18 (‐1.90 to 2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> </div> <p>We observed asymmetry in the funnel plot for the outcomes of response, suggesting the presence of small‐study effects or publication bias, such that studies with small or null effects are not in the public domain and were not uncovered by our sensitive searching (<a href="#CD010965-fig-0005">Figure 5</a>, Peters' regression test, P = 0.002). Sensitivity analysis for this outcome excluding four studies with the largest effect estimates and largest estimate of variance reduced the relative risk with 30% (RR 2.07, 95% CI 1.67 to 2.56). However, the funnel plots for other related outcomes were more symmetrical. No asymmetry was observed in funnel plots for change and rapid increase in serum sodium concentration, thirst, treatment discontinuation, and data for death, length of hospital stay, cognitive function, hypernatraemia or other adverse events were insufficient to allow for detection of small‐study effects. </p> <div class="figure" id="CD010965-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Vasopressin receptor antagonists versus placebo or no treatment, outcome: 1.6 Response in serum sodium concentration." data-id="CD010965-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Vasopressin receptor antagonists versus placebo or no treatment, outcome: 1.6 Response in serum sodium concentration. </p> </div> </div> </div> </section> <section id="CD010965-sec-0079"> <h5 class="title">Sensitivity analysis</h5> <p>Including the number of deaths occurring during follow‐up rather than during treatment had little effect on the estimate of the treatment effect (<a href="./references#CD010965-fig-0019" title="">Analysis 1.13</a> (16 studies, 2404 participants): RR 1.10, 95% CI 0.91 to 1.32). </p> <p>For the serum sodium concentration analysis, when we excluded seven studies judged at high or unclear risk of performance bias, the summary treatment estimate remained unchanged (14 studies, 1458 participants: MD 4.89 mmol/L, 95% CI 4.02 to 5.76). When we excluded eight studies judged at high or unclear risk of attrition bias, we found similar treatment effect estimates (13 studies, 1342 participants: MD 4.71 mmol/L, 95% CI 3.34 to 6.08). </p> </section> </section> <section id="CD010965-sec-0080"> <h4 class="title">Conivaptan versus conivaptan</h4> <p><a href="./references#CD010965-bbs2-0018" title="KalraS , EfratiS , ArthurJM , OlivenA , VelezJC , McNuttBE , et al. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia. American Journal of Health‐System Pharmacy2011;68(7):590‐8. [MEDLINE: 21411800] ">Kalra 2011</a> (117 participants) compared four regimens with or without a loading dose with one another and found no significant difference in any of the measured outcomes (death, change from baseline serum sodium concentration, response in serum sodium concentration, thirst, injection‐site phlebitis, injection‐site thrombosis, treatment discontinuation (data not shown). </p> </section> <section id="CD010965-sec-0081"> <h4 class="title">Tolvaptan versus tolvaptan</h4> <p><a href="./references#CD010965-bbs2-0030" title="ShoafSE , BricmontP , DandurandA . Low‐dose tolvaptan PK/PD: Comparison of subjects with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) to healthy adults [abstract]. Clinical Pharmacology and Therapeutics2017;101(Suppl 1):S88. [EMBASE: 614166327] ShoafSE , BricmontP , DandurandA . Low‐dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults. European Journal of Clinical Pharmacology2017;73(11):1399‐408. [MEDLINE: 28803333] ">Shoaf 2017</a> (30 participants) compared 3 single doses with one another and found rapid correction in 1, 1 and 2 subjects in the 3.75, 7.5, and 15 mg dose groups respectively, but only abstract data was available and the number of participants in each group was not reported (data not shown). </p> </section> <section id="CD010965-sec-0082"> <h4 class="title">Fluid restriction versus normal maintenance fluid treatment</h4> <p><a href="./references#CD010965-bbs2-0031" title="SinghiSC , SinghiPD , SrinivasB , NarakesriHP , GanguliNK , SialyR , et al. Fluid restriction does not improve the outcome of acute meningitis. Pediatric Infectious Disease Journal1995;14(6):495‐503. [MEDLINE: 7667054] ">Singhi 1995</a> (26 participants) compared fluid restriction (calculated as 65% of normal) versus normal maintenance intravenous fluid administration in children with bacterial meningitis. At two days, administration of restricted volumes significantly increased the serum sodium concentration (<a href="#CD010965-fig-0006">Figure 6</a> (1 study, 26 participants): MD 4.40 mmol/L, 95% CI 1.79 to 7.01), but had uncertain effects on the risk of death (<a href="#CD010965-fig-0006">Figure 6</a> (1 study, 26 participants): RR 7.80, 95% CI 0.46 to 131.62). </p> <div class="figure" id="CD010965-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Single study results" data-id="CD010965-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Single study results</p> </div> </div> </div> </section> <section id="CD010965-sec-0083"> <h4 class="title">Captopril and furosemide versus captopril</h4> <p><a href="./references#CD010965-bbs2-0006" title="DzauVJ , HollenbergNK . Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Annals of Internal Medicine1984;100(6):777‐82. [MEDLINE: 6372563] ">Dzau 1984</a> (14 participants) found after five days of treatment, the combination of captopril and furosemide resulted in a 10 mmol/L higher serum sodium concentration compared with captopril alone (<a href="#CD010965-fig-0006">Figure 6</a> (1 study, 14 participants): MD 10.00 mmol/L, 95% CI 8.60 to 11.40). The report did not include outcomes related to death, quality of life or adverse events due to rapid increases in serum sodium concentration caused by treatment. </p> </section> <section id="CD010965-sec-0084"> <h4 class="title">Albumin versus no treatment</h4> <p><a href="./references#CD010965-bbs2-0017" title="JalanR , MookerjeeR , CheshireL , WilliamsR , DaviesN . Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]. Journal of Hepatology2007;46(Suppl 1):S95. [CENTRAL: CN‐00653262] ">Jalan 2007</a> (24 participants) compared infusion of human salt poor albumin in combination with fluid and sodium restriction versus fluid and sodium restriction alone in patients with refractory ascites caused by liver cirrhosis. We only identified an abstract and it did not include any comparative data. </p> </section> <section id="CD010965-sec-0085"> <h4 class="title">Urea versus urea</h4> <p><a href="./references#CD010965-bbs2-0014" title="HayesPC , WilliamsR . Oral urea in the treatment of hyponatraemic ascites [abstract]. Gut1987;28(10):A1386. [CENTRAL: CN‐00221198] ">Hayes 1987</a> (10 participants) compared urea given immediately after development of hyponatraemia in people with ascites under diuretics versus urea given after a 'no treatment interval' of three days. We only identified an abstract and it did not include any comparative data. </p> </section> <section id="CD010965-sec-0086"> <h4 class="title">Medication change versus standard care</h4> <p><a href="./references#CD010965-bbs2-0022" title="Peyro Saint PaulL , MartinJ , GaillardC , MosquetB , CoquerelA , de laGastineB . Moderate potentially drug‐induced hyponatremia in older adults: benefit in drug reduction [L'hyponatremie moderee potentiellement medicamenteuse du sujet age: benefice de la reduction des medicaments]. Therapie2013;68(6):341‐6. [MEDLINE: 24246119] Peyro Saint PaulL , MartinJ , MosquetB , GaillardC , De LaGastineB . Benefit of pharmacological intervention on drug‐induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]. Fundamental &amp; Clinical Pharmacology2012;26(Suppl 1):74. [EMBASE: 70866717] ">NATRIPHAR 2013</a> (19 participants) compared a change in medication regimen to standard care in older adults suspected of having drug‐induced hyponatraemia. Compared with standard care, changing the medication regimen had uncertain effects on risk of death (<a href="#CD010965-fig-0006">Figure 6</a> (1 study, 19 participants): RR 0.37, 95% CI 0.02 to 8.01), response in serum sodium concentration (<a href="#CD010965-fig-0006">Figure 6</a> (1 study 14 participants): RR 10.11, 95% CI 0.68 to 150.68) and change from baseline in serum sodium concentration at one month (<a href="#CD010965-fig-0006">Figure 6</a> (1 study, 14 participants): MD 1.70, 95% CI ‐1.39 to 4.79). No participant in either group developed hypernatraemia or osmotic demyelination syndrome. </p> <p>No studies evaluated the effects of urea, mannitol, loop diuretics with or without oral sodium chloride, corticosteroids, demeclocycline, lithium or phenytoin with regard to correction of hyponatraemia. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010965-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010965-sec-0087"></div> <section id="CD010965-sec-0088"> <h3 class="title" id="CD010965-sec-0088">Summary of main results</h3> <p>This review included evidence from 35 randomised controlled trials involving 3429 participants, primarily covering vasopressin receptor antagonists. Generally, the evidence for patient‐important outcomes was limited. Vasopressin receptor antagonists had very uncertain effects on mortality and health‐related quality of life. There was low certainty evidence for a reduction in hospital stay (1.6 days) and for the absence of an important improvement in cognitive function. </p> <p>Most studies have focused on the intermediate biochemical outcome and there was moderate certainty evidence that vasopressin receptor antagonists increased the serum sodium concentration (4 mmol/L). But they were also associated with an increased risk of rapid serum sodium correction and commonly caused adverse effects such as thirst and polyuria. On average, treating 1000 people would cause 290 additional people to have an increase in serum sodium concentration of at least 5 mmol/L, but it would come at a cost of an additional 29 people having an increase exceeding 8 to 12 mmol/L/d, considered as the threshold from which on there is an increased risk for osmotic demyelination, be it that no such cases were documented in any of included studies. Effects were generally consistent across the different drugs in this class. RCT data for other interventions such as fluid restriction, urea, mannitol, loop diuretics, corticosteroids, demeclocycline, lithium and phenytoin were largely absent. </p> </section> <section id="CD010965-sec-0089"> <h3 class="title" id="CD010965-sec-0089">Overall completeness and applicability of evidence</h3> <p>Although the FDA and the EMA have approved certain vasopressin receptor antagonists for treating people with hyponatraemia, regulatory approval was largely based on intermediate outcomes in short‐term studies. To date, clinically important outcomes (e.g. reduction in all‐cause mortality or improvement in health‐related quality of life, cognitive and general functional status) remain insufficiently investigated. The data we had, indicated with moderate confidence that vasopressin receptor antagonists modestly increased the serum sodium concentration, but there is insufficient evidence to conclude this truly translates in the improvement of patient‐important outcomes. </p> <p>In the context of intervention studies, a surrogate or intermediate is a measurable outcome such as a laboratory test, which responds to an intervention (e.g. lowering of cholesterol with statins) and is causally associated a clinically important outcome (e.g. reduction in mortality with statins) (<a href="./references#CD010965-bbs2-0074" title="BallingerAE , PalmerSC , NistorI , CraigJC , StrippoliGF . Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD006254.pub2] ">Ballinger 2014</a>). Investigators often use surrogates instead of important health outcomes because surrogates can substantially reduce the cost, sample size and duration of a randomised trial. However, not all are valid proxies of clinically important outcomes. It is true that in acute and profound hyponatraemia, the evidence from observational studies is so overwhelming that we readily accept that increasing the serum sodium concentration is life‐saving. But as we move further from the extreme of acute, profound hyponatraemia into chronic, mild hyponatraemia, the evidence for such a consistent causal link weakens. Although it is true that a chronically low serum sodium concentration is strongly and consistently associated with increased mortality and risk of bone fractures (<a href="./references#CD010965-bbs2-0096" title="WaldR , JaberBL , PriceLL , UpadhyayA , MadiasNE . Impact of hospital‐associated hyponatremia on selected outcomes. Archives of Internal Medicine2010;170(3):294‐302. [MEDLINE: 20142578] ">Wald 2010</a>), there is currently insufficient evidence that aside from affecting the surrogate (e.g. increase in serum sodium concentration with a vasopressin receptor antagonist) treatment in case of more chronic hyponatraemia also changes the patient‐important outcomes downstream of the surrogate in the same causal pathway (e.g. reduction in mortality as a consequence of raising serum sodium concentration with a vasopressin receptor antagonist). There are intuitive reasons to assume that such causality can reasonably be extrapolated to the entire spectrum of hypotonic hyponatraemia. But likewise, there are reasons for caution. Lixivaptan primarily failed to obtain regulatory approval by the FDA for hyponatraemia in chronic heart failure due to a numeric ‐ be it statistically non‐significant ‐ imbalance in early deaths. The clinical review team argued that 'while the early death in participants with chronic heart failure and hyponatraemia could reflect the underlying disease, they could not exclude the possibility that some subjects with hyponatraemia associated with acute worsening congestive failure were exquisitely sensitive to intravascular free water shifts and did not tolerate even a small change in intravascular volume status or osmolality, induced by lixivaptan and/or effects resulting from a compensatory neurohumoral activation' (<a href="./references#CD010965-bbs2-0003" title="FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012. deals.bio/home/download?doc_id=911 (accessed 28 June 2018):1‐217. AbrahamWT , ArandaJM , BoehmerJP , ElkayamU , GilbertEM , GottliebSS , et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clinical &amp; Translational Science2010;3(5):249‐53. [MEDLINE: 20973922] Cardiokine BiopharmaLLC . Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio‐Renal Drugs Advisory Committee Meeting. www.wayback.archive‐it.org/7993/20170404150420/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM320625.pdf (accessed 18 January 2018). FDA Center for Drug Evaluation and Research. A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012. www.wayback.archive‐it.org/7993/20170722221724/https://www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm (accessed 18 January 2018). ">BALANCE 2010</a>). </p> <p>Studies contributing to this review included mostly participants with mild to moderate hyponatraemia (mean serum sodium concentration at study level ≥ 123 mmol/L). Meta‐regression revealed a modifying effect of the serum sodium concentration at baseline, with lower values associated with larger increases in natraemia. Extrapolation of meta‐regression data would suggest higher increases, but possibly higher risks of rapid correction as the baseline serum sodium decreases. Although no study reported osmotic demyelination, it is unclear what would happen if vasopressin receptor antagonists were used on a larger scale and in people with sodium concentrations below those included in the RCTs that contributed to this review. Likewise, it is possible that while improvements in cognitive function were not readily detected, they would emerge for people with lower serum sodium concentrations at baseline. </p> <p>Finally, studies evaluating the effectiveness of alternative interventions for increasing serum sodium concentration in people with chronic, non‐hypovolaemic hyponatraemia are largely absent. </p> </section> <section id="CD010965-sec-0090"> <h3 class="title" id="CD010965-sec-0090">Quality of the evidence</h3> <p>Overall, we considered the data evaluating the effects of vasopressin receptor antagonists for people with chronic, non‐hypovolaemic, hypotonic hyponatraemia on patient‐important outcomes such as mortality, health‐related quality of life, and hospital stay limited and of low certainty. Low certainty evidence suggests that additional studies are likely to change our confidence in the effects (<a href="./references#CD010965-bbs2-0077" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). According to GRADE, RCT data is considered high quality, but may be downgraded for several reasons (<a href="./references#CD010965-bbs2-0078" title="GuyattGH , OxmanAD , SchünemannHJ , TugwellP , KnottnerusA . GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2010;64:380‐382. [MEDLINE: 21185693] ">Guyatt 2010</a>). These reasons varied for each outcome. For death it was largely driven by the width of the confidence interval, which captured both appreciable benefit and harm, and left us with considerably uncertainty around the treatment effect. For health‐related quality of life, there was some evidence that vasopressin receptor antagonists increased the mental component summary score of the SF‐12, and unclear effects on the physical component summary score. However, we serious questioned the validity of this tool for measuring quality of life in the context of hyponatraemia. For one thing, many items included in the SF‐12 do not reflect readily acknowledged signs and symptoms of hyponatraemia (e.g. bodily pain, anxiety) and similarly, the neurocognitive signs of hyponatraemia are not assessed by the tool. In addition to the general content validity issues, we also judged effects for this self‐reported outcome may have been inflated because participants were likely unblinded due to polyuria as a side‐effect; results were selectively reported for one in two measurement time‐points; and more than one‐third of the data were missing. </p> <p>We had more extensive data for outcomes related to serum sodium concentration, resulting in moderate confidence in the effect estimates all around. Downgrading occurred mainly for missing outcome data, which we judged could have somewhat overestimated the treatment effect; as well as indirectness, in that tight follow‐up during dose‐titration, is likely to have avoided rapid correction somewhat in the trial setting. It may result in higher risk of rapid correction when used in clinical practice. </p> <p>Of note, all studies assessing benefits and harms of vasopressin receptor antagonists were likely instigated and sponsored by the pharmaceutical company developing or seeking to commercialise the compound. For the studies that provided a declaration of interest for the authors of study reports, all save one had author lists that featured people who had received money for presentations or consultancy, or were employed by the sponsor. Industry sponsorship does not necessarily introduce bias into the design and conduct of clinical trials, but empiric evidence does show that pharmaceutical industry‐sponsored studies are more likely to have favourable efficacy results (RR 1.32, 95% CI 1.21 to 1.44) and harm results (RR 1.87, 95% CI 1.54 to 2.27) than studies not sponsored by industry (<a href="./references#CD010965-bbs2-0085" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2012</a>). </p> <p>Data for other interventions such as fluid restriction, change in medical regimens, captopril or albumin were sparse and inconclusive. </p> </section> <section id="CD010965-sec-0091"> <h3 class="title" id="CD010965-sec-0091">Potential biases in the review process</h3> <p>Although this review was conducted by two or more independent authors, used a comprehensive search of the published and unpublished research designed by a specialist librarian, and examined all potentially relevant clinical outcomes, potential biases exist in the review process. The major weakness of this review is the paucity of data for treatments other than vasopressin receptor antagonists. First, summary of existing evidence therefore focusses the discourse on new, and expensive, treatments, rather than focusing on existing, and cheaper alternatives. RCTs are extraordinarily expensive and consequently often conducted by the pharmaceutical industry. This results in a catch‐22 situation of evidence being mostly created, and thus only available, for newer interventions in general. Many other interventions are or have been used in clinical practice, but were driven to the background because RCT data were largely absent. Notably, also for fluid restriction, despite it being the currently accepted first‐line treatment for both hypervolaemic and euvolaemic hyponatraemia, there are no randomised trial data available. Currently, there are limited opportunities for use of vasopressin receptor antagonists in practice. Only two vasopressin receptor antagonists have obtained large scale regulatory approval. Conivaptan is FDA approved for euvolaemic and hypervolaemic hyponatraemia in hospitalised patients. It is available only as an intravenous preparation and treatment duration is limited to a maximum duration of four days because of drug‐interaction effects with other agents metabolized by the cytochrome P450 3A4 hepatic isoenzyme (<a href="./references#CD010965-bbs2-0076" title="USFood , DrugAdministration . FDA briefing document for the Cardiovascular and Renal Drug Advisory (CRDAC) ‐ Drug: Lixivaptan. www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm318867.pdf (accessed 30 January 2014). ">FDA 2012</a>). Tolvaptan, an oral agent, is also FDA‐approved for the treatment of euvolaemic and hypervolaemic hyponatraemia. Although theoretically available for long‐term treatment, recent concerns around the potential for severe liver injury in patients with autosomal dominant polycystic kidney disease ‐ be it at doses far exceeding the ones used in hyponatraemia ‐ has caused the FDA to restrict the use of tolvaptan to 30 days and issue a contra‐indication for patients with underlying liver disease (<a href="./references#CD010965-bbs2-0086" title="Mirski , D (Otsuka America Pharmaceutical , Inc) . Potential risk of liver injury with use of SAMSCA® (tolvaptan). www.sefap.it/web/upload/UCM336675.pdf 22 January 2013. ">Mirski 2013</a>). Canadian regulatory authorities mandated monitoring liver injury tests at regular intervals, but did not limit duration of use. In the European Union, tolvaptan is approved only for the treatment of euvolaemic hyponatraemia, due to safety concerns stemming from a numeric ‐ be it statistically non‐significant ‐ difference in treatment‐emergent fatalities in patients with hypervolaemia. </p> </section> <section id="CD010965-sec-0092"> <h3 class="title" id="CD010965-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p>This review largely agreed with the findings of two earlier systematic reviews. However, neither of these previous reviews sought to examine any other treatments beyond vasopressin receptor antagonists for treating chronic non‐hypovolaemic hypotonic hyponatraemia. The first, including 15 RCTs and 1619 participants found vasopressin antagonists on average increased the serum sodium concentration by approximately 5 mmol/L at one week (13 studies, 1119 participants: MD 5.27 mmol/L, 95% CI 4.27 to 6.26), and approximately 3.5 mmol/L beyond the first week (8 studies, 793 participants: MD 3.49 mmol/L, 95% CI 2.56 to 4.41), but it came at a cost of increased risk of overly rapid correction of the serum sodium concentration (8 studies, 860 participants: RR, 2.52, 95% CI 1.26 to 5.08) (<a href="./references#CD010965-bbs2-0089" title="Rozen‐ZviB , YahavD , GheorghiadeM , KorzetsA , LeiboviciL , GafterU . Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta‐analysis. American Journal of Kidney Diseases2010;56(2):325‐37. [MEDLINE: 20538391] ">Rozen‐Zvi 2010</a>).The second review, including 11 RCTs and 1094 participants, found vasopressin antagonists on average increased the serum sodium concentration by approximately 5 mmol/L at day 4 (11 studies, 1094 participants: MD 4.90 mmol/L, 95% CI 4.10 to 5.80), but was associated with a 6% increased risk of overly rapid correction of the serum sodium concentration (9 studies, 995 participants: RD 0.06, 95% CI 0.03 to 0.10) (<a href="./references#CD010965-bbs2-0082" title="JaberBL , AlmarzouqiL , BorgiL , SeabraVF , BalkEM , MadiasNE . Short‐term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. American Journal of Medicine2011;124(10):977.e1‐9. [MEDLINE: 21962320] ">Jaber 2011</a>). </p> <p>We also largely agreed with the interpretation of these data by the respective study authors as presented in their discussion: vasopressin receptor antagonists effectively raise the serum sodium concentration. But whether this translates to meaningful changes in outcomes that matter to patients is not clear. At this stage the available RCTs have insufficiently studied clinical outcomes to conclude that people whose serum sodium concentration increases under treatment will experience changes in end‐points such as general well‐being, cognitive function, gait stability, bone fractures and survival. </p> <p>In 2013, a guideline group consisting of seven authors (six Americans and one Irishman), published expert recommendations identifying several alternative treatments, including fluid restriction, demeclocycline, urea and vasopressin receptor antagonists. Driven by the emergence of RCT evidence for vasopressin receptor antagonists as effective means for increasing the serum sodium concentration, and the absence of such evidence for other treatments, they projected vasopressin receptor antagonists were likely to become a mainstay of treatment for euvolaemic hyponatraemia and probably represented the best approach to treating hyponatraemia in most oedema‐forming states (<a href="./references#CD010965-bbs2-0095" title="VerbalisJG , GoldsmithSR , GreenbergA , KorzeliusC , SchrierRW , SternsRH , et al. Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. American Journal of Medicine2013;126(10 Suppl 1):S1‐42. [MEDLINE: 17981159] ">Verbalis 2013</a>). </p> <p>A European guideline published in 2014 ‐ to which four authors of this review contributed ‐ suggested that in moderate or profound hyponatraemia (serum sodium concentration &lt; 130 mmol/L), restricting fluid intake was first‐line treatment (2D); increasing solute intake with urea or a combination of low‐dose loop diuretics and oral sodium chloride were equal second‐line treatments (2D); and vasopressin receptor antagonists were not recommended (1C). (<a href="./references#CD010965-bbs2-0092" title="SpasovskiG , VanholderR , AllolioB , AnnaneD , BallS , BichetD , et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia.[Erratum appears in Nephrol Dial Transplant. 2014 Jun;40(6):924]. Nephrology Dialysis Transplantation2014;29(Suppl 2):i1‐i39. [MEDLINE: 24569496] ">Spasovski 2014</a>). There is almost no RCT evidence for treatments other than vasopressin receptor antagonists. The group's rationale to advocate some of these treatments anyway stemmed from the premise that in the absence of unequivocal evidence that increasing the serum sodium concentration leads to an improvement in patient‐important outcomes, the focus should be on avoiding harm. They gave much weight to avoiding rapid increases in the serum sodium concentration, for it's ‐ albeit very rare ‐ association with osmotic demyelination syndrome. And based on the absence of observational evidence for rapid increases or other important harms for fluid restriction, urea and low‐dose loop diuretics with oral sodium chloride, they formulated a weak recommendation to consider these for treating people with sodium concentrations below 130 mmol/L. Largely because of the documented risk of rapid increase and some concern around its potential for liver disease, a negative recommendation was formulated for vasopressin receptor antagonists. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010965-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010965-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010965-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010965-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Effect of baseline serum sodium concentration on change in natraemia: meta‐regression" data-id="CD010965-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Effect of baseline serum sodium concentration on change in natraemia: meta‐regression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Vasopressin receptor antagonists versus placebo or no treatment, outcome: 1.6 Response in serum sodium concentration." data-id="CD010965-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Vasopressin receptor antagonists versus placebo or no treatment, outcome: 1.6 Response in serum sodium concentration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Single study results" data-id="CD010965-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Single study results</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 1 Death at 6 months." data-id="CD010965-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 1 Death at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 2 Health‐related quality of life." data-id="CD010965-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 2 Health‐related quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 3 Cognitive function: trail making test Part B." data-id="CD010965-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 3 Cognitive function: trail making test Part B. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 4 Length of hospital stay." data-id="CD010965-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 4 Length of hospital stay. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 5 Change from baseline serum sodium concentration." data-id="CD010965-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 5 Change from baseline serum sodium concentration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 6 Response in serum sodium concentration." data-id="CD010965-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 6 Response in serum sodium concentration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 7 Rapid increase in serum sodium concentration." data-id="CD010965-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 7 Rapid increase in serum sodium concentration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 8 Hypernatraemia during treatment." data-id="CD010965-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 8 Hypernatraemia during treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 9 Thirst." data-id="CD010965-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 9 Thirst. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 10 Other adverse events." data-id="CD010965-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 10 Other adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 11 Injection‐site complications at 2 to 7 days." data-id="CD010965-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 11 Injection‐site complications at 2 to 7 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 12 Treatment discontinuation." data-id="CD010965-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 12 Treatment discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 13 Death during follow‐up: sensitivity analysis." data-id="CD010965-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 13 Death during follow‐up: sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010965-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/urn:x-wiley:14651858:media:CD010965:CD010965-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_t/tCD010965-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 14 Rapid increase in serum sodium concentration: sensitivity analysis." data-id="CD010965-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Vasopressin receptor antagonists (VRA) versus placebo or no treatment, Outcome 14 Rapid increase in serum sodium concentration: sensitivity analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/media/CDSR/CD010965/image_n/nCD010965-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010965-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vasopressin receptor antagonists versus placebo or no treatment for chronic non‐hypovolaemic hypotonic hyponatraemia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Vasopressin receptor antagonists versus placebo or no treatment for chronic non‐hypovolaemic hypotonic hyponatraemia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> chronic non‐hypovolaemic hypotonic hyponatraemia<br/> <b>Intervention:</b> Vasopressin receptor antagonists<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Vasopressin receptor antagonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Death</p> <p>Follow‐up: range 2 to 180 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/> (0.92 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2330 (15)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Interpretation: effect uncertain; may both result in 11/1000 fewer to 47/1000 more deaths within 6 months </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/> (132 to 190) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life (assessed with mental component score of SF‐12<sup>4</sup>) </p> <p>Follow‐up: 30 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in health‐related quality of life in the control group ranged between 0.75 and 2.39 on a 0 to 100 point scale (worst to best) <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean health‐related quality of life in the intervention group was 4.76 higher (0.11 higher to 9.41 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW <sup>6, 7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physical component score also measured in both studies; RR 1.04; CI ‐1.81 to 3.90</p> <p>Interpretation: anywhere from 0.1 to 9.5/100 points higher increase with treatment, but questionable tool for QoL measurement in hyponatraemia and unclear minimally important clinical difference </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Length of hospital stay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay in the control group was 6 to 11 days <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean length of hospital stay in the intervention group was 1.63 days lower (2.96 lower to 0.30 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>580 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>8,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive function</p> <p>(assessed with various tools)</p> <p>Follow‐up: 1 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Across five studies, confidence intervals spanned the line of no effect and did not include a clinically meaningful effect </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1169 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW <sup>10</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tools used to assess cognitive function: making test B; reaction time, psychomotor, processing speeds; Mini mental state exam; overall meta‐analysis including all five studies not meaningfully possible </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change from baseline in serum sodium concentration</p> <p>Follow‐up: range 1 to 180 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in serum sodium concentration in the control group was 0.3 to 4.8 mmol/L <sup>5</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in serum sodium concentration in the intervention group was 4.17 mmol/L higher (3.18 higher to 5.16 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2641 (21)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serum sodium concentration (response)</p> <p>Follow‐up: range 4 to 180 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.49<br/> (1.95 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2104 (18)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>11</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Response most commonly defined by investigators as &gt; 5 to &gt; 6 mmol/L increase or normalisation of serum sodium concentration </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>231 per 1000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>576 per 1000<br/> (454 to 597) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rapid sodium increase</p> <p>Follow‐up: range 1 to 5 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.67<br/> (1.16 to 2.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2058 (14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>12</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Rapid increase most commonly defined as &gt; 12 mmol/d</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000 <sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<br/> (51 to 105) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Source of assumed baseline risk was calculated as the unweighted summed event rate in the control groups of the trials included in the meta‐analysis </p> <p><sup>2</sup> Downgraded one level because studies considered at serious risk of suffering from </p> <p>* selective reporting: 6/16 studies with treatment duration &gt; 1 week did not report death and had no protocol, accounting for 16% of the total number of participants in those studies </p> <p>* commercial sponsorship; possible financial conflict of interest of the authors: all studies sponsored by pharmaceutical companies wanting to commercialize the treatment; all save one had author lists who featured people who had received money for presentations or consultancy, or were employed by the sponsor; only used as supporting reason for downgrading. </p> <p><sup>3</sup> Downgraded two levels for imprecision. The 95% CI of the pooled estimate includes both important reduction (11/1000 fewer) and increase (47/1000 more) in death with vasopressin receptor antagonists. </p> <p><sup>4</sup> Choice of the outcome‐measure based on the fact that this was the only one reported in any of the studies. There are concerns around the validity of the SF‐12 as a measure for health‐related quality of life in the field of hyponatraemia as it gauges domains and symptoms not directly attributable to hyponatraemia. </p> <p><sup>5</sup> Source of the assumed baseline risk was the range of outcomes in the control groups of the trials included in the meta‐analysis </p> <p><sup>6</sup> Downgraded one level because studies considered seriously at risk of suffering from </p> <p>* Performance bias: self‐reported outcome, participants likely unblinded to treatment due to polyuria as side effect </p> <p>* Selective reporting bias: both mental and physical component score of SF‐12 measured; at week 1 or 2 and day 30 using two different analytic techniques. Only data at day 30 available for analysis. </p> <p>* Attrition bias: overall 37% of data missing, unknown whether missing at random or not. </p> <p>* Commercial sponsorship or possible financial conflict of interest of authors: both studies were sponsored by the company seeking to commercialise the treatment; both had author lists who featured people who had received money for presentations or consultancy, or were employed by the sponsor; only using as supporting argument for downgrading </p> <p><sup>7</sup> Downgraded one level for indirectness due to concerns around validity of the SF‐12 for measuring quality of life in the context of hyponatraemia and one level for imprecision: only studied in two studies. </p> <p><sup>8</sup> Downgraded one level because studies considered seriously at risk of suffering from performance bias: participants and personnel likely unblinded to treatment due to polyuria as side effect; this could have influenced self‐reported and professional appreciation of clinical condition and so have influenced decision to discharge from hospital. </p> <p><sup>9</sup> Downgraded one level for imprecision. The 95% CI of the pooled estimate includes both negligible shortening (0.3 days shorter) and clinically important shortening (3 days shorter) of hospital stay with vasopressin receptor antagonists. </p> <p><sup>10</sup> Downgraded two levels for indirectness and imprecision. Only studied in 5/28 studies, with most data for lixivaptan, and other studies not reaching the optimal information size. </p> <p><sup>11</sup> Downgraded one level because we considered studies seriously at risk of suffering from </p> <p>* Attrition bias: 7/21 studies, accounting for 53% of the total number of participants in those studies at high risk of bias either due to true attrition or because a repeated measures analytic technique was used with all measurements of serum sodium concentration included until patient attrition, which we judged would likely have overestimated the treatment effect. </p> <p>*Commercial sponsorship; only used as supporting argument.</p> <p><sup>12</sup> Downgraded one level for indirectness; risks controlled in tightly organised randomised trial with several measurements of serum sodium concentration daily to avoid rapid correction. In real life, risk of rapid correction likely greater. Commercial sponsorship bias; only used as supporting argument. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vasopressin receptor antagonists versus placebo or no treatment for chronic non‐hypovolaemic hypotonic hyponatraemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010965-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Change in serum sodium concentration: meta‐regression and confounding</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Covariate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of studies included in meta‐regression</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Scale</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Absolute change in mean difference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline serum sodium concentration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per 1 mmol/L increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.33 (‐0.65 to ‐0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Compound</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative to conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.79 (‐5.47 to ‐0.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Satavaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0,23 (‐3.34 to 2.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.82 (‐3.13 to 1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Cause of hyponatraemia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative to SIADH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIADH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Combined SIADH ‐ Heart failure, cirrhosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 (‐1.77 to 3.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.19 (‐3.84 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Treatment duration</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Per day increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.02 (‐0,04 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Risk of selection bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative to low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18 (‐1.90 to 2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Change in serum sodium concentration: meta‐regression and confounding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/full#CD010965-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010965-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vasopressin receptor antagonists (VRA) versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.92, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.13, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.85, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.89, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Mental component SF‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.76 [0.11, 9.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Physical component SF‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [‐1.81, 3.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cognitive function: trail making test Part B <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.89 [‐6.34, 20.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Length of hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.63 [‐2.96, ‐0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Satavaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐3.80, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐3.28, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change from baseline serum sodium concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.17 [3.18, 5.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.17 [2.65, 7.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [0.78, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Satavaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.91 [2.88, 6.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [3.55, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Response in serum sodium concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.95, 3.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [1.54, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [1.19, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Satavaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [1.88, 5.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.75, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Rapid increase in serum sodium concentration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.16, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.77 [0.89, 15.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.90, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Satavaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.61 [0.73, 9.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.70 [0.82, 54.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hypernatraemia during treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.63, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.14, 57.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.04, 5.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Satavaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.35, 11.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>941</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.81, 9.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Thirst <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.80, 4.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Polyuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [1.59, 13.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.75, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Acute kidney injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.67, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Liver function abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.88, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Injection‐site complications at 2 to 7 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.56 [0.49, 115.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Phlebitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.52 [1.00, 12.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Thrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.21, 14.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.85, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.39, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Satavaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.17, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.66, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Death during follow‐up: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.91, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Conivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.19, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Lixivaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>950</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.37, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Tolvaptan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.89, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Rapid increase in serum sodium concentration: sensitivity analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.16, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 &gt; 8 mmol/L/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.22 [0.65, 15.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 &gt; 12 mmol/L/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.09, 2.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vasopressin receptor antagonists (VRA) versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010965.pub2/references#CD010965-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010965.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010965-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010965-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010965-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010965-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD010965-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD010965-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010965-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010965\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010965\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010965\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010965\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010965\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010965.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010965.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010965.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010965.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010965.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724615689"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010965.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724615693"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010965.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6723ba52f44a',t:'MTc0MDcyNDYxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 